

CELL THERAPEUTICS INC
Form 10-Q/A
February 06, 2007
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q/A
(Amendment No. 1)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: June 30, 2006

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____ to _____

Commission File Number 001-12465

CELL THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Washington
(State or other jurisdiction of
incorporation or organization)

91-1533912
(I.R.S. Employer Identification No.)

501 Elliott Avenue West, Suite 400
Seattle, Washington
(Address of principal executive offices)

98119
(Zip Code)

(206) 282-7100

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act. (Check one):

Edgar Filing: CELL THERAPEUTICS INC - Form 10-Q/A

Large accelerated filer Accelerated filer Non-accelerated filer

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:

| Class | Outstanding at July 31, 2006 |
|----------------------------|-------------------------------------|
| Common Stock, no par value | 109,666,245 |

Table of Contents

CELL THERAPEUTICS, INC.

TABLE OF CONTENTS

| | PAGE |
|--|-------------|
| PART I - FINANCIAL INFORMATION | |
| ITEM 1: Financial Statements | |
| <u>Condensed Consolidated Balance Sheets at June 30, 2006 and December 31, 2005</u> | 4 |
| <u>Condensed Consolidated Statements of Operations Three and Six Months Ended June 30, 2006 and 2005</u> | 5 |
| <u>Condensed Consolidated Statements of Cash Flows Six Months Ended June 30, 2006 and 2005</u> | 6 |
| <u>Notes to Condensed Consolidated Financial Statements</u> | 7 |
| ITEM 2: <u>Management's Discussion and Analysis of Financial Condition and Results of Operations.</u> | 19 |
| ITEM 3: <u>Quantitative and Qualitative Disclosures About Market Risk</u> | 30 |
| ITEM 4: <u>Controls and Procedures</u> | 30 |
| <u>Report of Independent Registered Public Accounting Firm</u> | 31 |
| PART II - OTHER INFORMATION | |
| ITEM 1: <u>Legal Proceedings</u> | 32 |
| ITEM 1A: <u>Risk Factors</u> | 33 |
| ITEM 4: <u>Submission of Matters to a Vote of Security Holders</u> | 44 |
| ITEM 6: <u>Exhibits</u> | 45 |
| <u>Signatures</u> | 46 |

Table of Contents

Explanatory Note:

Cell Therapeutics, Inc., or CTI, is filing this Amendment No. 1 on Form 10-Q/A to its Form 10-Q for the quarter ended June 30, 2006, to reflect the restatement of its previously issued financial statements to correct inadvertent errors in accounting for accounts payable and accrued expenses in our Italian subsidiary, Cell Therapeutics Europe, S.r.l., or CTI (Europe).

The information contained in this Amendment, including the financial statements and the notes hereto, amends only Items 1, 2 and 4 of Part I and Item 1A of Part II of our originally filed Quarterly Report on Form 10-Q for the quarter ended June 30, 2006 and no other items in our originally filed Form 10-Q are amended hereby. In accordance with Rule 12b-15 of the Securities and Exchange Act of 1934, the complete text of those items in which amended language appears is set forth herein, including those portions of the text that have not been amended from that set forth in the original Form 10-Q. Except for the aforementioned adjustments, this Form 10-Q/A does not materially modify or update other disclosures in the original Form 10-Q, including the nature and character of such disclosure to reflect events occurring after August 9, 2006, the filing date of the original Form 10-Q. Accordingly this Form 10-Q/A should be read in conjunction with our filings made with the Securities and Exchange Commission. Currently dated certifications from our Chief Executive Officer and Chief Financial Officer have been included as exhibits to this amendment.

Impact on Management's Assessment of Internal Control over Financial Reporting: In connection with the restatement, we reevaluated our disclosure controls and procedures in CTI (Europe). We concluded that our failure to correctly account for accounts payable and accrued expenses constituted a material weakness in our internal control over financial reporting. As a result of this material weakness, we concluded that our disclosure controls and procedures in relation thereto were not effective as of June 30, 2006.

Remediation of Material Weakness: In an effort to remediate the material weakness described above, we are currently implementing enhanced procedures that are designed to ensure that we will properly record accounts payable and accrued expenses in CTI (Europe). These enhanced procedures will provide for additional managerial oversight of accounts payable and accrued expense balances.

Table of Contents**CELL THERAPEUTICS, INC.****CONDENSED CONSOLIDATED BALANCE SHEETS****(In thousands, except share amounts)**

| | June 30, 2006 (unaudited) | December 31, 2005 |
|---|--|------------------------------|
| | (restated) | |
| ASSETS | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 30,681 | \$ 50,022 |
| Restricted cash | 65 | 25,596 |
| Securities available-for-sale | 17,209 | 18,858 |
| Interest receivable | 220 | 187 |
| Accounts receivable, net | 510 | 2,306 |
| Prepaid expenses and other current assets | 9,525 | 10,107 |
| Total current assets | 58,210 | 107,076 |
| Property and equipment, net | 10,323 | 12,278 |
| Goodwill | 17,064 | 17,064 |
| Other intangibles, net | 2,013 | 2,239 |
| Other assets | 13,825 | 16,783 |
| Total assets | \$ 101,435 | \$ 155,440 |
| LIABILITIES AND SHAREHOLDERS DEFICIT | | |
| Current liabilities: | | |
| Accounts payable | \$ 1,193 | \$ 3,370 |
| Accrued expenses | 15,197 | 17,558 |
| Current portion of deferred revenue | 80 | 80 |
| Current portion of long-term obligations | 2,692 | 2,880 |
| Current portion of convertible senior notes | | 6,900 |
| Total current liabilities | 19,162 | 30,788 |
| Deferred revenue, less current portion | 518 | 558 |
| Other long-term obligations, less current portion | 5,993 | 7,326 |
| 7.5% convertible senior notes | 57,391 | |
| 6.75% convertible senior notes | 7,662 | 72,146 |
| Convertible senior subordinated notes | 82,557 | 122,079 |
| Convertible subordinated notes | 28,490 | 29,640 |
| Commitments and contingencies | | |
| Shareholders' deficit: | | |
| Preferred stock, no par value: | | |
| Authorized shares - 10,000,000 | | |
| Series C, 100,000 shares designated, none issued or outstanding | | |
| Common stock, no par value: | | |
| Authorized shares - 200,000,000 | | |
| Issued and outstanding shares - 109,678,079 and 73,421,721 at June 30, 2006 and December 31, 2005, respectively | 798,419 | 721,544 |
| Deferred stock-based compensation | | (1,669) |
| Accumulated other comprehensive loss | (1,080) | (1,683) |

Edgar Filing: CELL THERAPEUTICS INC - Form 10-Q/A

| | | |
|---|------------|------------|
| Accumulated deficit | (897,677) | (825,289) |
| Total shareholders' deficit | (100,338) | (107,097) |
| Total liabilities and shareholders' deficit | \$ 101,435 | \$ 155,440 |

See accompanying notes.

Table of Contents**CELL THERAPEUTICS, INC.****CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS****(In thousands, except per share amounts)****(unaudited)**

| | Three Months Ended June 30, | | Six Months Ended June 30, | |
|--|--|--------------------|--------------------------------------|--------------------|
| | 2006 | 2005 | 2006 | 2005 |
| | (restated) | | (restated) | |
| Revenues: | | | | |
| Product sales | \$ | \$ 7,372 | \$ | \$ 13,409 |
| License and contract revenue | 20 | 96 | 40 | 199 |
| Total revenues | 20 | 7,468 | 40 | 13,608 |
| Operating expenses: | | | | |
| Cost of product sold | | 212 | | 458 |
| Research and development | 15,164 | 20,179 | 30,928 | 42,242 |
| Selling, general and administrative | 8,317 | 17,649 | 18,420 | 36,975 |
| Amortization of purchased intangibles | 199 | 242 | 388 | 495 |
| Restructuring charges and related asset impairments | (118) | 1,972 | 342 | 1,972 |
| Total operating expenses | 23,562 | 40,254 | 50,078 | 82,142 |
| Loss from operations | (23,542) | (32,786) | (50,038) | (68,534) |
| Other income (expense): | | | | |
| Investment and other income | 694 | 432 | 1,236 | 912 |
| Interest expense | (4,708) | (3,994) | (13,336) | (7,887) |
| Foreign exchange gain | 821 | 173 | 1,112 | 202 |
| Make-whole interest expense | (4,374) | | (24,540) | |
| Gain on derivative liabilities | 2,659 | | 6,083 | |
| Gain on exchange of convertible notes | 7,978 | | 7,978 | |
| Settlement expense | | | (883) | |
| Other income (expense), net | 3,070 | (3,389) | (22,350) | (6,773) |
| Net loss | \$ (20,472) | \$ (36,175) | \$ (72,388) | \$ (75,307) |
| Basic and diluted net loss per share | \$ (0.20) | \$ (0.57) | \$ (0.74) | \$ (1.19) |
| Shares used in calculation of basic and diluted net loss per share | 104,600 | 63,336 | 97,340 | 63,320 |

See accompanying notes.

Table of Contents**CELL THERAPEUTICS, INC.****CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS****(In thousands)****(unaudited)**

| | Six Months Ended June 30, | |
|---|--------------------------------------|-------------|
| | 2006 (restated) | 2005 |
| Operating activities | | |
| Net loss | \$ (72,388) | \$ (75,307) |
| Adjustments to reconcile net loss to net cash used in operating activities: | | |
| Depreciation and amortization | 3,234 | 4,817 |
| Equity-based compensation expense | 2,502 | 1,645 |
| Loss on disposition of property and equipment | 76 | 54 |
| Amortization of investment premium | 134 | 239 |
| Non-cash gain on exchange of convertible notes | (7,978) | |
| Non-cash gain on derivative liabilities | (6,083) | |
| Non-cash interest expense | 9,257 | 3,026 |
| Asset impairments | | 2,242 |
| Non-cash rent (benefit) expense | (8) | 90 |
| Gain on sale of investment securities | | 14 |
| Changes in operating assets and liabilities: | | |
| Restricted cash | 859 | |
| Interest receivable | (32) | 22 |
| Accounts receivable, net | 1,346 | (71) |
| Inventory | | (37) |
| Prepaid expenses and other current assets | 784 | (387) |
| Other assets | 417 | (435) |
| Accounts payable | (2,371) | (2,261) |
| Accrued expenses | (1,799) | (7,093) |
| Deferred revenue | (40) | (181) |
| Excess facilities obligations | (1,391) | |
| Other long-term obligations | (276) | 592 |
| Total adjustments | (1,369) | 2,276 |
| Net cash used in operating activities | (73,757) | (73,031) |
| Investing activities | | |
| Purchases of securities available-for-sale | (16,961) | (26,139) |
| Proceeds from sales of securities available-for-sale | | 15,815 |
| Proceeds from maturities of securities available-for-sale | 18,488 | 8,926 |
| Purchases of property and equipment | (348) | (1,944) |
| Proceeds from sale of property and equipment | 511 | |
| Net cash provided by (used in) investing activities | 1,690 | (3,342) |
| Financing activities | | |
| Proceeds from issuance of 7.5% convertible senior notes, net | 31,177 | |
| Release of restricted cash related to 6.75% convertible senior notes | 24,712 | |

Edgar Filing: CELL THERAPEUTICS INC - Form 10-Q/A

| | | |
|---|------------------|------------------|
| Mandatory redemptions of 6.75% convertible senior notes | (2,655) | |
| Proceeds from common stock sold via the employee stock purchase plan | 17 | 215 |
| Repayment of long-term obligations | (57) | (742) |
| Net cash provided by (used) in financing activities | 53,194 | (527) |
| Effect of exchange rate changes on cash and cash equivalents | (468) | (1,893) |
| Net decrease in cash and cash equivalents | (19,341) | (78,793) |
| Cash and cash equivalents at beginning of period | 50,022 | 105,033 |
| Cash and cash equivalents at end of period | \$ 30,681 | \$ 26,240 |
| Supplemental disclosure of cash flow information | | |
| Cash paid during the period for interest | \$ 29,055 | \$ 4,863 |
| Cash paid for taxes | \$ | \$ |
| Supplemental disclosure of noncash financing and investing activities | | |
| Conversion of 6.75% convertible senior notes to common stock | \$ 68,645 | \$ |
| Conversion of 7.5% convertible senior notes to common stock | \$ 7,375 | \$ |
| Conversion of convertible senior subordinated notes to common stock | \$ 4 | \$ |
| Extinguishment of 5.75% convertible senior subordinated notes in exchange for 7.5% convertible senior notes | \$ 39,518 | \$ |
| Extinguishment of 5.75% convertible subordinated notes in exchange for 7.5% convertible senior notes | \$ 1,150 | \$ |
| Issuance of 7.5% convertible senior notes in exchange for 5.75% subordinated and senior subordinated notes | \$ 33,156 | \$ |

See accompanying notes.

Table of Contents

CELL THERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

1. Description of Business and Summary of Significant Accounting Policies

Description of Business

Cell Therapeutics, Inc., or CTI or the Company, focuses on the development, acquisition and commercialization of drugs for the treatment of cancer. Our principal business strategy is focused on cancer therapeutics, an area with significant market opportunity that we believe is not adequately served by existing therapies. Our operations are primarily conducted in the United States and Italy. Our Italian operations commenced on January 1, 2004, the effective date of our merger with Novuspharma S.p.A., or Novuspharma, an Italian biopharmaceutical company focused on cancer therapeutics.

Basis of Presentation

The accompanying unaudited financial information of CTI as of June 30, 2006 and for the three and six months ended June 30, 2006 and 2005 has been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, such financial information includes all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the Company's financial position at such date and the operating results and cash flows for such periods. Operating results for the three and six month periods ended June 30, 2006 are not necessarily indicative of the results that may be expected for the entire year. These financial statements and the related notes should be read in conjunction with our audited annual financial statements for the year ended December 31, 2005 included in our Form 10-K/A.

The balance sheet at December 31, 2005 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements.

Liquidity

Cash and cash equivalents, restricted cash, securities available for sale and interest receivable are approximately \$48.2 million as of June 30, 2006. We expect that this amount will not be sufficient to fund our operations for the next 12 months. Accordingly, we will need to raise additional funds and are currently exploring alternative sources of equity or debt financing. Additional funding may not be available on favorable terms or at all. If we are unable to raise additional capital in the near term, we have developed a plan to further curtail operations significantly, by delaying, modifying, or canceling selected aspects of research and development programs related to XYOTAX, pixantrone and other products we may be developing. The plan contains reductions in operating expenditures related to certain research and development and general and administrative activities including compensation and benefits, corporate costs and clinical trial costs, which are designed to allow the company to continue to operate on a going concern basis.

Product Sales

We recognized revenue from product sales when there was persuasive evidence that an arrangement existed, title had passed and delivery had occurred, the price was fixed and determinable, and collectability was reasonably assured. Because we sold our only commercial product, TRISENOX, to Cephalon on July 18, 2005, there were no product sales subsequent to this date. Product sales were generally recorded upon shipment net of an allowance for returns and discounts. Customers were able to return damaged or expired inventory for up to one year after the expiration date. Estimated returns were based on historical returns and sales patterns. If we were unable to reasonably estimate returns related to a particular customer or market, we deferred revenue recognition until return

Table of Contents

rights had expired. There was no allowance for returns, discount and bad debts at June 30, 2006 or December 31, 2005 as all trade receivables were sold in connection with the divestiture of TRISENOX to Cephalon.

License and Contract Revenue

We may generate revenue from technology licenses, collaborative research and development arrangements, cost reimbursement contracts and research grants. Revenue under technology licenses and collaborative agreements typically consists of nonrefundable and/or guaranteed technology license fees, collaborative research funding, and various milestone and future product royalty or profit-sharing payments.

Revenue associated with up-front license fees and research and development funding payments under collaborative agreements is recognized ratably over the relevant periods specified in the agreement, generally the research and development period. If the time period is not defined in the agreement, we calculate the revenue recognition period based on our current estimate of the research and development period considering experience with similar projects, level of effort and the stage of development. Should there be a change in our estimate of the research and development period, we will revise the term over which the initial payment is recognized. Revenue from substantive at-risk milestones and future product royalties is recognized as earned based on the completion of the milestones and product sales, as defined in the respective agreements. Revenue under cost reimbursement contracts and research grants is recognized as the related costs are incurred. Payments received in advance of recognition as revenue are recorded as deferred revenue.

We evaluate multiple element arrangements pursuant to Emerging Issues Task Force, or EITF, 00-21, *Revenue Arrangements with Multiple Deliverables*. For multiple element arrangements that have continuing performance obligations, we recognize contract, milestone or license fees together with any up-front payments over the term of the arrangement as we complete our performance obligation, unless the delivered technology has stand alone value to the customer and there is objective, reliable evidence of fair value of the undelivered element in the arrangement. Additionally, pursuant to the guidance of Securities and Exchange Commission Staff Accounting Bulletin 104, or SAB 104, unless evidence suggests otherwise, revenue from consideration received is recognized on a straight-line basis over the expected term of the arrangement.

Research and Development Expenses

Research and development expenses include related salaries and benefits, clinical trial and related manufacturing costs, contract and other outside service fees, and facilities and overhead costs related to our research and development efforts. Research and development expenses also consist of costs incurred for proprietary and collaboration research and development and include activities such as product registries and investigator-sponsored trials. Research and development costs are expensed as incurred. Generally, in instances where we enter into agreements with third parties for research and development activities, costs are expensed upon the earlier of when non-refundable amounts are due or as services are performed unless there is an alternative future use of the funds in other research and development projects. Amounts due under such arrangements may be either fixed fee or fee for service, and may include upfront payments, monthly payments, and payments upon the completion of milestones or receipt of deliverables.

Impairment of Long-lived Assets

We review our long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows to the recorded value of the asset. If an impairment is indicated, the asset is written down to its estimated fair value based on quoted fair market values.

Table of Contents

Value Added Tax Receivable

Our European subsidiary is subject to Value Added Tax, or VAT, which is usually applied to all goods and services purchased and sold throughout Europe. The VAT receivable is approximately \$9.6 million and \$8.9 million as of June 30, 2006 and December 31, 2005, respectively, of which \$9.0 million and \$8.3 million is included in *other assets* as of June 30, 2006 and December 31, 2005, respectively and \$0.6 million is included in *prepaid expenses and other current assets* as of both dates. This receivable balance typically has a three to five year collection period. We review our VAT receivable balance for impairment whenever events or changes in circumstances indicate the carrying amount might not be recoverable.

Net Loss Per Share

Basic net loss per share is calculated based on the net loss divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted earnings per share assumes the conversion of all dilutive convertible securities, such as convertible debt using the if-converted method, and assumes the exercise or vesting of other dilutive securities, such as options, warrants and share awards using the treasury stock method. As of June 30, 2006 and 2005, options, warrants, unvested share awards and rights and convertible debt aggregating 47,160,622 and 24,110,916, common equivalent shares, respectively, prior to the application of the treasury stock method for options and warrants, were not included in the calculation of diluted net loss per share as they are anti-dilutive.

Derivatives Embedded in Certain Debt Securities

We evaluate financial instruments for freestanding or embedded derivatives in accordance with Statement of Financial Accounting Standards, or SFAS, No. 133, *Accounting for Derivative Instruments and Hedging Activities*, and related guidance. Derivative instruments are recorded at fair value with changes in value recognized in the period of change.

Our 6.75% convertible senior notes, or 6.75% notes, and our 7.5% convertible senior notes, or 7.5% notes, contain certain features providing for payments in cash or common stock to be made in the event of certain conversions or repurchases of the debt. In the event of any conversion of our 6.75% notes to common stock, the feature calls for make-whole payments equal to the interest on the debt over its term less any amounts paid prior to the date of the conversion. Our 7.5% notes include a feature that calls for make-whole payments in the event of automatic conversion or if the holder requires us to repurchase the notes upon certain non-stock changes in control (see Note 4, *Convertible Senior Notes*). This payment is equal to \$225 per \$1,000 principal amount of the notes less any interest amounts paid prior to the date of conversion or repurchase.

These make-whole features represent embedded derivatives which are required to be accounted for separately from the related debt securities. The fair value of the derivative for the 6.75% notes is calculated based on a discounted cash flow model. The fair value of the derivative related to the 7.5% notes is calculated using a Monte Carlo simulation model that incorporates factors such as the current price of our common stock, its volatility, and time to expiration of the make-whole feature. Changes in the estimated fair value of the liabilities are included in *gain on derivative liabilities* and will be calculated until the relevant feature expires or all of the relevant notes are converted or repurchased.

Table of Contents*Foreign Currency Translation*

For our operations that have a functional currency other than the U.S. dollar, gains and losses resulting from the translation of the functional currency into U.S. dollars for financial statement presentation are not included in determining net loss but are accumulated in the cumulative foreign currency translation adjustment account as a separate component of shareholders' deficit in accordance with SFAS 52, *Foreign Currency Translation*.

Recently Issued Accounting Pronouncements

In July 2006, the Financial Accounting Standards Board, or FASB, issued FASB Interpretation Number, or FIN, 48, *Accounting for Uncertainty in Income Taxes, an Interpretation of FASB Statement No. 109*, which clarifies the accounting for uncertainty in tax positions. This interpretation will require that we recognize the effect of a tax position in our financial statements, if there is a greater likelihood than not of the position being sustained upon audit, based on the technical merits of the position. The provisions of FIN 48 are effective beginning January 1, 2007, with the cumulative effect of the change in accounting principle recorded as an adjustment to the opening balance of deficit. We are currently evaluating the impact that FIN 48 will have on our consolidated financial statements.

2. Restatement

In the fourth quarter of 2006, we discovered the following errors in CTI (Europe):

A \$1.0 million accounts payable balance to Micromet AG, or Micromet, which had been recorded by CTI (Europe) prior to its acquisition by the Company in January 2004. In May 2006, we settled a dispute with Micromet whereby we paid Micromet \$1.9 million to settle all outstanding claims between the two companies. Accordingly, the outstanding payable balance should have been reversed with a corresponding offset to settlement expense at the time we recorded the settlement charge in the first quarter of 2006.

In March 2006, CTI (Europe) received a \$251,000 payment from a clinical trial vendor. The payment represented a settlement of prior amounts paid to the vendor for which the company claimed it had not received services. The Company made the claim in December 2005 and at December 31, 2005 the claim represented a gain contingency and was not recorded due to significant uncertainty around receipt of payment. Upon receipt of payment in March 2006 the payment was inadvertently recorded as accounts payable rather than a reduction of research and development expense.

In the second quarter of 2006 CTI (Europe) inadvertently continued to record accruals for clinical trial activities that had been transferred to CTI Seattle in the first quarter of 2006. These accruals amounted to approximately \$548,000 as of June 30, 2006. The following tables summarize the effect of the restatement adjustments on the financial statements as of and for the three and six months ended June 30, 2006:

| | As Filed | June 30, 2006 (in thousands) Adjustments | Restated |
|--------------------------------------|-----------|--|-----------|
| Accounts payable | \$ 2,480 | \$ (1,287) | \$ 1,193 |
| Accrued expenses | 15,745 | (548) | 15,197 |
| Total current liabilities | 20,997 | (1,835) | 19,162 |
| Accumulated other comprehensive loss | (1,100) | 20 | (1,080) |
| Accumulated deficit | (899,492) | 1,815 | (897,677) |
| Total shareholders' deficit | (102,173) | 1,835 | (100,338) |

Three Months Ended June 30, 2006
(in thousands)

Edgar Filing: CELL THERAPEUTICS INC - Form 10-Q/A

| | As Filed | Adjustments | Restated |
|--------------------------|-----------|-------------|-----------|
| Research and development | \$ 15,692 | \$ (528) | \$ 15,164 |
| Total operating expenses | 24,090 | (528) | 23,562 |
| Loss from operations | (24,070) | 528 | (23,542) |
| Net loss | (21,000) | 528 | (20,472) |

| Six Months Ended June 30, 2006 (in thousands, except per share data) | | | |
|---|-----------|-------------|-----------|
| | As Filed | Adjustments | Restated |
| Research and development | \$ 31,707 | \$ (779) | \$ 30,928 |
| Total operating expenses | 50,857 | (779) | 50,078 |
| Loss from operations | (50,817) | 779 | (50,038) |
| Settlement expense | (1,919) | 1,036 | (883) |
| Other expense, net | (23,386) | 1,036 | (22,350) |
| Net loss | (74,203) | 1,815 | (72,388) |
| Basic and diluted net loss per share | \$ (0.76) | \$ 0.02 | \$ (0.74) |

The adjustments to the balance sheet and income statement as of and for the three and six months ended June 30, 2006 had no impact on total cash flows from operating, investing and financing activities.

3. Comprehensive Loss

Comprehensive loss is comprised of net loss and other comprehensive income or loss. SFAS 130, *Reporting Comprehensive Income*, provides for unrealized gains and losses on our securities available-for-sale and our former interest rate swap agreement which was designated as a cash flow hedge, to be included in other comprehensive loss. Also included are net exchange gains or losses resulting from the translation of assets and liabilities of foreign subsidiaries. Total comprehensive loss was \$20.2 million and \$38.5 million for the three month periods ended June 30, 2006 and 2005, respectively. Total comprehensive loss was \$71.8 million and \$78.7 million for the six month periods ended June 30, 2006 and 2005, respectively.

Information regarding the components of accumulated other comprehensive loss is as follows (in thousands):

| | June 30, 2006 (restated) | December 31, 2005 |
|--|--------------------------------|----------------------|
| Foreign currency translation adjustment | \$ (1,074) | \$ (1,663) |
| Net unrealized loss on securities available-for-sale | (6) | (20) |
| Accumulated other comprehensive loss | \$ (1,080) | \$ (1,683) |

4. Stock-Based Compensation Expense

On January 1, 2006, we adopted SFAS 123(R), *Share-Based Payment (Revised 2004)*, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options, share awards, and employee stock purchases related to the Employee Stock Purchase Plan, or employee stock purchases, based on estimated fair values. SFAS 123(R) supersedes our previous accounting under Accounting Principles Board Opinion, or APB, No. 25, *Accounting for Stock Issued to Employees*, for periods beginning in fiscal 2006. In March 2005, the Securities and Exchange Commission issued Staff Accounting Bulletin, or SAB, No. 107 relating to SFAS 123(R). We have applied the provisions of SAB 107 in our adoption of SFAS 123(R).

We adopted SFAS 123(R) using the modified prospective transition method, which requires the application of the accounting standard as of January 1, 2006, the first day of our fiscal year 2006. Our Condensed Consolidated Financial Statements as of and for the three and six months ended June 30, 2006 reflect the impact of SFAS 123(R). In accordance with the modified prospective transition method, our Condensed Consolidated Financial Statements for prior periods have not been restated to reflect, and do not include, the impact of SFAS 123(R). Stock-based compensation expense recognized under SFAS 123(R) for the three months ended June 30, 2006 was \$1.2 million, which consisted of \$0.7 million of stock-based compensation expense related to employee stock options and employee stock purchases and \$0.5 million of stock-based compensation expense related to share awards. Stock-based compensation expense recognized for the six months ended June 30, 2006 was \$2.5 million, which consisted of \$1.6 million related to employee stock options and employee stock purchases and \$0.9 million related

Edgar Filing: CELL THERAPEUTICS INC - Form 10-Q/A

to share awards. Stock-based compensation expense recognized for share awards was \$0.9 million and \$1.7 million during the three and six months ended June 30, 2005, respectively. There was no stock-based compensation expense related to employee stock options and employee stock purchases recognized during the three and six months ended June 30, 2005.

SFAS 123(R) requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our Condensed Consolidated Statement of Operations. Prior to the adoption of SFAS 123(R), we accounted for stock-based awards to employees and directors using the intrinsic value

Table of Contents

method in accordance with APB 25 as allowed under SFAS 123, *Accounting for Stock-Based Compensation*. Under the intrinsic value method, no stock-based compensation expense related to stock options had been recognized in our Condensed Consolidated Statement of Operations because the exercise price of our stock options granted to employees and directors equaled the fair market value of the underlying stock at the date of grant.

Stock-based compensation expense recognized during the period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Stock-based compensation expense recognized in our Condensed Consolidated Statement of Operations for the three and six months ended June 30, 2006 included 1) compensation expense for share-based payment awards granted prior to, but not yet vested as of December 31, 2005 based on the grant date fair value estimated in accordance with the pro forma provisions of SFAS 123 and 2) compensation expense for the share-based payment awards granted subsequent to January 1, 2006 based on the grant date fair value estimated in accordance with the provisions of SFAS 123(R). We use the straight-line single-option method to recognize the value of stock-based compensation expense for all share-based payment awards granted after January 1, 2006. Expense is recognized using the graded-vesting multiple-option method for options granted prior to January 1, 2006. As stock-based compensation expense recognized in the Condensed Consolidated Statement of Operations for the three and six months ended June 30, 2006 is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. SFAS 123(R) requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. In our pro forma information required under SFAS 123 for the periods prior to fiscal 2006, we accounted for forfeitures as they occurred.

The following table summarizes stock-based compensation expense related to employee stock options, employee stock purchases, and share awards under SFAS 123(R) for the three and six months ended June 30, 2006, which was allocated as follows (in thousands):

| | Three Months Ended | Six Months Ended |
|--|---------------------------|-------------------------|
| | June 30, 2006 | June 30, 2006 |
| Research and development | \$ 508 | \$ 1,079 |
| Selling, general and administrative | 697 | 1,423 |
| Stock-based compensation expense included in operating expenses | \$ 1,205 | \$ 2,502 |

Stock-based compensation had a \$1.2 million and \$2.5 million effect on our net loss for the three and six months ended June 30, 2006, respectively, no effect on cash flows from operations or financing activities and had a \$(0.01) and \$(0.03) effect on basic and diluted net loss per share for the three and six month periods ending June 30, 2006, respectively.

The weighted average fair value of employee stock options granted in the three months ended June 30, 2006 and 2005 was \$0.77 and \$1.91, respectively. The weighted average fair value of employee stock options granted in the six months ended June 30, 2006 and 2005 was \$0.99 and \$4.44, respectively. This does not take into account the fair value of 180,000 contingent stock options granted in June 2006 which will vest upon the achievement of certain performance goals.

Table of Contents

SFAS 123(R) requires the disclosure of pro-forma information for periods prior to the adoption. The following table illustrates the effect on net loss and net loss per share for the three and six months ended June 30, 2005 if we had recognized compensation expense for all share-based payments to employees based on their fair values (in thousands, except per share amounts):

| | Three Months | Six Months |
|---|----------------------|----------------------|
| | Ended | Ended |
| | June 30, 2005 | June 30, 2005 |
| Net loss, as reported | \$ (36,175) | \$ (75,307) |
| Add: Stock-based employee compensation included in reported net loss | 901 | 1,692 |
| Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards | (2,099) | (4,128) |
| Pro forma net loss | \$ (37,373) | \$ (77,743) |
| Basic and diluted net loss per share: | | |
| As reported | \$ (0.57) | \$ (1.19) |
| Pro forma | \$ (0.59) | \$ (1.23) |

Fair value was estimated at the date of grant using the Black-Scholes pricing model, with the following weighted average assumptions:

| | Three Months Ended | | Six Months Ended | |
|--------------------------|---------------------------|-----------------|-------------------------|-----------------|
| | June 30, | June 30, | June 30, | June 30, |
| | 2006 | 2005 | 2006 | 2005 |
| Risk-free interest rates | 5.1% | 3.8% | 4.9% | 3.9% |
| Expected dividend yield | None | None | None | None |
| Expected life (in years) | 2.7 | 4.1 | 3.2 | 4.1 |
| Volatility | 74% | 97% | 74% | 97% |

The risk-free interest rate used in the Black-Scholes valuation method is based on the implied yield currently available in U.S. Treasury securities at maturity with an equivalent term. We have not declared or paid any dividends and do not currently expect to do so in the future. The expected term of options represents the period that our stock-based awards are expected to be outstanding and was determined based on historical weighted average holding periods and projected holding periods for the remaining unexercised shares. Consideration was given to the contractual terms of our stock-based awards, vesting schedules and expectations of future employee behavior. Expected volatility is based on the annualized daily historical volatility, including consideration of the implied volatility and market prices of traded options for comparable entities within our industry.

Our stock price volatility and option lives involve management's best estimates, both of which impact the fair value of the option calculated under the Black-Scholes methodology and, ultimately, the expense that will be recognized over the life of the option. SFAS 123(R) also requires that we recognize compensation expense for only the portion of options expected to vest. Therefore, we applied an estimated forfeiture rate that we derived from historical employee termination behavior. If the actual number of forfeitures differs from our estimates, additional adjustments to compensation expense may be required in future periods.

Stock compensation expense for options granted to non-employees has been determined in accordance with SFAS 123 and EITF 96-18, *Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling, Goods or Services*, at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. The fair value of options granted to non-employees is periodically remeasured as the underlying options vest.

Table of Contents

No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for substantially all net deferred tax assets.

Stock Option Plans

During 2003, shareholders approved the 2003 Equity Incentive Plan, or 2003 Plan, which replaced the 1994 Equity Incentive Plan, or 1994 Plan. The 1994 Plan has since been terminated, except with respect to outstanding awards previously granted thereunder. The 2003 Plan provides for (a) the grant of nonqualified and/or incentive stock options, stock appreciation rights and share awards, (b) annual, automatic, non-discretionary grants of non-qualified stock options and share awards to non-employee members of our board of directors and (c) the award of stock-based performance bonuses. There are 6,443,289 shares authorized under the 2003 Plan including the authorization for issuance of an additional 5,000,000 shares of common stock as set forth in an August 2004 amendment to the 2003 Plan approved by our shareholders at our 2004 Annual Meeting of Shareholders and 293,289 shares which had been reserved but not granted under the 1994 Plan.

The Novuspharma S.p.A. Stock Option Plan, or 2004 Plan, authorized 350,000 shares and provides for the grant of nonqualified and/or incentive stock options and share awards to employees, consultants and directors in Italy.

The Plans are administered by the Compensation Committee of the Board of Directors which has the discretion to determine which employees, consultants and directors shall be granted options. The options are typically exercisable ratably over a four-year period commencing one year from the date of grant, and expire not more than 10 years from the date of grant. As of June 30, 2006, approximately 454,000 shares of common stock were available for future grants.

The following table summarizes stock option activity for all of stock option plans during the six months ended June 30, 2006:

| | | | Weighted | |
|---|----------------|-----------------|--------------------|--------------------|
| | | Weighted | Average | Aggregate |
| | | Average | Remaining | Intrinsic |
| | | Exercise | Contractual | Value |
| | Options | Price | Term | (Thousands) |
| Outstanding December 31, 2005 | 6,115,000 | \$ 10.95 | | |
| Granted | 721,000 | \$ 1.73 | | |
| Exercised | | \$ | | |
| Forfeited | (160,000) | \$ 5.83 | | |
| Expired | (377,000) | \$ 13.78 | | |
| Outstanding June 30, 2006 | 6,299,000 | \$ 9.86 | 7.1 | \$ 9 |
| Vested or expected to vest at June 30, 2006 | 5,776,000 | \$ 10.44 | 7.2 | \$ |
| Exercisable at June 30, 2006 | 4,071,000 | \$ 13.34 | 6.4 | \$ |

Table of Contents

A summary of the status of nonvested share awards as of June 30, 2006 and changes during the period then ended, is presented below:

| | Nonvested | Fair Value |
|-----------------------------------|------------------|-------------------|
| | Shares | Per Share |
| Nonvested at December 31, 2005 | 1,608,000 | \$ 4.92 |
| Granted | 76,000 | \$ 1.76 |
| Vested | (372,000) | \$ 3.90 |
| Forfeited | (61,000) | \$ 2.91 |
| Nonvested at June 30, 2006 | 1,251,000 | \$ 5.13 |

The total fair value of share awards vested during the six months ended June 30, 2006 was \$609,000.

As of June 30, 2006, the total remaining unrecognized compensation cost related to unvested stock options and share awards amounted to \$2.4 million, which will be amortized over the weighted-average remaining requisite service period of 1.0 years. This amount does not include unrecognized compensation cost related to 650,000 shares of contingent share awards granted during 2005 and 180,000 contingent stock options granted in June 2006 which will vest upon the achievement of certain performance goals.

5. Convertible Senior Notes*6.75% Convertible Senior Notes*

As of June 30, 2006, \$71.6 million of our 6.75% notes due 2010 had been converted into 27.3 million shares of common stock, resulting in cumulative make-whole interest payments of \$23.9 million which was paid in cash. In addition, certain holders of the notes exercised their right to redeem up to 30% aggregate principal of their notes, and on April 30, 2006, we redeemed approximately \$2.7 million in aggregate principal of these notes. Subsequent to this date the mandatory redemption right expired and the remaining cash which we held in escrow to fund the potential redemptions was returned to us. As of June 30, 2006, we had \$7.7 million principal amount of 6.75% notes outstanding.

The interest make-whole provision of the 6.75% convertible senior notes due 2010 represents an embedded derivative which is required to be accounted for separate from the underlying 6.75% senior notes and was recorded as a derivative liability and a discount to the carrying value of the notes. The resulting discount to the notes is being accreted over the life of the notes as additional interest expense using the effective interest method. Accordingly, we recorded interest expense of \$0.6 million and \$3.9 million for the three and six months ended June 30, 2006, respectively, primarily in connection with the note conversions. The estimated fair value of the derivative liability was \$0.3 million at June 30, 2006 and was recorded in *6.75% convertible senior notes*. The change in the estimated fair value for the three and six months ended June 30, 2006 of \$0.6 million and \$4.0 million, respectively, is recorded as *gain on derivative liabilities*.

7.5% Convertible Senior Notes

In April 2006, we issued approximately \$66.3 million aggregate principal amount of our 7.5% notes, approximately \$33.2 million of which was issued in a registered offering for cash with net proceeds of approximately \$31.2 million, after deducting expenses and the initial purchasers discounts and commissions. Approximately \$33.2 million was issued in a private exchange for approximately \$39.5 million aggregate principal amount of our 5.75% convertible senior subordinated notes and approximately \$1.2 million aggregate principal amount of our 5.75% convertible subordinated notes. We recognized a net gain of \$8.0 million on the early extinguishment and exchange of these notes which is based on the carrying value of the exchanged notes less the fair value of the new notes, net of issuance costs of \$0.4 million and accrued interest of \$0.9 million attributable to the exchanged notes. We recorded

Table of Contents

issuance costs related to 7.5% notes of approximately \$2.0 million which are recorded in *other assets* and are being amortized to interest expense using the effective interest method over the five-year life of the notes.

The notes are convertible, at the option of the holder, into shares of our common stock at any time prior to maturity, redemption or repurchase at an initial conversion rate of 478.519 shares of common stock per \$1,000 principal amount of the notes, which is subject to adjustments in certain circumstances. This conversion rate is equivalent to a conversion price of approximately \$2.09 per share. On or after April 30, 2009, we have the option to redeem all of the notes for cash at any time at a redemption price equal to par plus accrued and unpaid interest up to but not including the redemption date. Subject to certain conditions, the notes will automatically convert if, at any time after June 26, 2006 and prior to maturity, the closing price per share of our common stock has exceeded 125% of the conversion price then in effect for at least 20 trading days within any 30-consecutive trading day period. In addition, upon certain non-stock changes in control, the holder can require us to repurchase the notes at 100% of their principal amount, plus accrued and unpaid interest to, but not including, the repurchase date. Upon any automatic conversion of the notes, or if the holder exercises their right to require us to repurchase notes in connection with a non-stock change of control, we will pay the holder of the notes a make-whole interest payment equal to \$225 per \$1,000 principal amount of the notes so converted, less any interest paid on such notes prior to the conversion date.

In May 2006, approximately \$7.4 million of the 7.5% notes were converted into 3.5 million shares. In connection with the conversions, we made an interest make-whole payment of \$1.7 million as a one-time concession which is included in *make-whole interest expense*. As of June 30, 2006, we had \$58.9 million principal amount of 7.5% notes outstanding.

The interest make-whole provision, included in the note indenture and described above, represents an embedded derivative which is required to be accounted for separate from the underlying 7.5% notes. At the issuance of the 7.5% notes, the interest make-whole feature was estimated to have a fair value of approximately \$3.7 million and the initial recorded value of the 7.5% notes was reduced by this allocation. The resulting discount to the notes will be accreted over the life of the notes as additional interest expense using the effective interest method, of which \$0.5 million was recorded for the three and six months ended June 30, 2006. The estimated fair value of the derivative liability will be adjusted quarterly for changes in the estimated market value. The change in the estimated fair value for the three and six months ended June 30, 2006 was \$2.1 million and included in *gain on derivative liabilities*. At June 30, 2006, the fair value of the derivative was \$1.6 million and was recorded in *7.5% convertible senior notes*.

Our evaluation of the embedded make-whole feature was made in accordance with SFAS 133. We determined that the make-whole provision meets the definition of an embedded derivative because 1) the economic characteristics of the make-whole provision are not clearly and closely related to those of the host instrument because they could at least double the investor's rate of return and result in a rate of return that is at least twice that of a market rate of return for a similar instrument, 2) the host convertible debt instrument is not remeasured at fair value and 3) if the make-whole provision were a separate instrument with the same terms it would meet the definition of a derivative.

We determined that the conversion feature in the notes did not result in a beneficial conversion feature based on the guidance in EITF 00-27, *Application of Issue No. 98-5 to Certain Convertible Instruments*.

6. Restructuring Activities

During 2005, we reduced our workforce in the U.S. and Europe and terminated our aircraft lease. In conjunction with our workforce reduction we vacated a portion of our laboratory and office facilities and recorded an excess facility charge.

Table of Contents

The following table summarizes the changes in the liability for restructuring activities during six months ended June 30, 2006 (in thousands):

| | Excess Facilities Charges | Employee Separation Costs |
|------------------------------|--------------------------------------|--------------------------------------|
| Balance at December 31, 2005 | \$ 6,334 | \$ 1,925 |
| Adjustments | 338 | |
| Payments | (1,729) | (1,925) |
| Balance at June 30, 2006 | \$ 4,943 | \$ |

Excess Facilities Charges

Charges for excess facilities relate to our lease obligation for excess laboratory and office space in the U.S. that we have vacated as a result of the restructuring plan. Pursuant to SFAS 146, we recorded restructuring charges in 2005 when we ceased using this space. The liability is calculated as the present value of total lease commitments, net of estimated sublease income. The additional charges for the six months ended June 30, 2006 were due to changes in our estimate of the timing and amount of cash flows related to these excess facilities as well as adjustments due to the passage of time. We will periodically evaluate our existing needs, the current and estimated future values of our subleases, and other future commitments to determine whether we should record additional excess facilities charges or adjustments to such charges. As of June 30, 2006, approximately \$2.4 million of the liability for restructuring activities is included in *current portion of long-term obligations* and approximately \$2.5 million is included in *other long-term obligations, less current portion*.

7. Equity Financing Agreement

On June 21, 2006, we entered into a Step-Up Equity Financing Agreement with Société Générale. Subject to certain conditions, the agreement allows us to issue to Société Générale shares of our common stock in a series of tranches over a period of 24 months. The agreement allows us to initially issue up to 45 million worth of our common stock based on a pre-determined formula and gives us the right to increase the total amount of all issuances to up to 60 million worth of our common stock. Any issuance of our common stock pursuant to this agreement is at our election and we are not required to issue any common stock.

Société Générale's obligation to purchase shares upon request by CTI is subject to certain conditions, including approvals from Italian regulatory authorities. If this approval is not obtained or otherwise deemed not required by September 30, 2006, the agreement will terminate as of this date. As of June 30, 2006, there have not been any shares of common stock issued under this agreement.

8. Prepaid Supply Agreement

In September 2001, we entered into a purchase agreement with Natural Pharmaceuticals, Inc., or NPI, to purchase \$6.0 million of paclitaxel, a starting material for XYOTAX, which was to be delivered by NPI over several years. This material was intended to be used primarily for research and development activities. We paid for the entire purchase upon execution of the agreement in 2001 and recorded the amount as a prepaid asset. As we had adequate supply of paclitaxel on hand to support our validation campaigns and clinical activities, we amended our supply agreement with NPI in October 2005 to reduce the amount of material we would receive and we were refunded \$0.8 million of our prepayment. In addition, the amended agreement grants NPI the exclusive right to purchase up to 5 kilograms of our paclitaxel supply at our original cost through September 1, 2006. In January 2006, CTI and NPI amended the agreement to allow NPI the right to sell some or all of the paclitaxel supply to its customers and replace the material within 60 days with newer material having a longer expiration date.

As of June 30, 2006 and December 31, 2005, we had paclitaxel supply of \$1.7 million and \$2.3 million, respectively, which is included in *prepaid expenses and other current assets*. The amount as of June 30, 2006 includes approximately \$0.1 million in supply due from NPI. These costs have been capitalized since there is a ready market for this active pharmaceutical ingredient.

Table of Contents

9. Legal Proceedings

On February 10, 2004, Micromet AG, or Micromet, a Munich, Germany-based company, filed complaints against CTI in the federal district court for the Western District in the State of Washington, asserting that Cell Therapeutics Europe S.r.l., or CTI-Europe, formerly known as Novuspharma S.p.A., had purportedly breached a contract with Micromet for the development of MT-201, a fully human antibody targeting the EP-CAM molecule. The claims alleged that CTI-Europe failed to pay for certain milestones and development expenses owed under the contract. On February 23, 2004, CTI answered the complaint, denying the substance of the allegations and filed counterclaims for breach of contract and for rescission of the contract based on Micromet's misrepresentations and failures to disclose material information including preclinical trial tests which were determined to be invalid. On May 3, 2006, CTI and Micromet entered into a settlement and release regarding this lawsuit pursuant to which CTI paid Micromet approximately \$1.9 million in cash and the lawsuit was dismissed with prejudice.

Beginning in March 2005, a number of purported shareholder class actions, alleging violations of federal securities laws, were filed against CTI, James Bianco and Max Link. These actions have been consolidated in the United States District Court for the Western District of Washington. On November 7, 2005, the plaintiffs filed a Consolidated and Amended Class Action Complaint against CTI, James Bianco and Jack Singer. The Consolidated and Amended Complaint asserts claims arising under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder on behalf of a class of purchasers of common stock during the period from November 14, 2003 to March 7, 2005, or the Class Period. Plaintiffs alleged that the defendants violated federal securities laws by, among other things, making false statements of material facts and/or omitting to state material facts to make the statements not misleading in connection with the results of the Company's STELLAR clinical trials for its drug XYOTAX. On January 6, 2006, CTI filed a motion to dismiss this class action complaint. On May 4, 2006 the Court granted CTI's motion to dismiss this lawsuit with leave to the plaintiffs to amend. On June 8, 2006 the Court entered a dismissal of this lawsuit with prejudice.

On May 9, 2005, Terence Fernandes, a shareholder of CTI, filed a complaint in the Superior Court of the State of Washington, King County on behalf of CTI against members of CTI's board of directors. The shareholder derivative action alleges breaches of fiduciary duties, abuse of control, gross mismanagement, waste of corporate assets and unjust enrichment since June 7, 2004. The case now resides in the United States District Court for the Western District of Washington. On December 7, 2005, plaintiff filed an amended complaint and defendants filed a motion to dismiss on February 6, 2006, to which plaintiffs responded on March 10, 2006. Defendants filed a reply brief on April 10, 2006. On June 22, 2006 the Court granted CTI's motion to dismiss this lawsuit with leave to the plaintiffs to amend. The period of time for the plaintiffs to amend the complaint has tolled. On July 31, 2006 defendants filed a motion to dismiss this lawsuit with prejudice for the failure of the plaintiffs to amend the complaint. No estimate of possible loss or range of loss resulting from the lawsuit can be made at this time.

The United States Attorney's Office, or USAO, for the Western District of Washington is conducting an investigation into certain of CTI's business practices relating to TRISENOX. USAO's investigation relates to CTI's promotional practices relating to TRISENOX; its reporting of revenue relating to TRISENOX sales; and statements made by CTI representatives, and its expert third party reimbursement consultant, relating to the eligibility of TRISENOX for Medicare reimbursement when the drug was used to treat certain off-label indications. USAO has issued subpoenas to third parties relating to its investigation. CTI is fully cooperating with USAO (through the provision of documents and periodic meetings) and has not received a subpoena relating to the matter. Management cannot predict whether USAO will bring formal criminal enforcement proceedings (and USAO has not indicated that it will). Claims associated with the above-referenced as well as related conduct have been filed against the Company under seal on behalf of the government by a private party in a qui tam action. Based on information currently available to the Company, we believe that the USAO may recommend to the Department of Justice that the government intervene in the qui tam action, as is its right, and assume the conduct of this lawsuit. We believe that regardless of whether the government or the private party pursues this lawsuit that one of the primary claims that might be pursued would be that CTI violated the Federal False Claims Act by receiving reimbursement from Medicare for improper off-label use of TRISENOX or otherwise ineligible sales of TRISENOX over the period ranging from October 2000 until TRISENOX's disposition to Cephalon in July of 2005. During this period the Company utilized a third party reimbursement expert. The Company believes it has meritorious defenses to these claims. It is unclear to the Company under this theory what sales or portions thereof would be in question.

Table of Contents

Accordingly, CTI cannot provide an estimate of a possible loss or range of loss in connection with this investigation or lawsuit. Under the False Claims Act, damages can be trebled and separate fines imposed for each violation, if the government or the private party plaintiff were to prevail in this lawsuit it is likely that such an adverse judgment would have a material adverse effect on our financial position, liquidity and results of operations.

We have not recorded a reserve for any of the above matters as of June 30, 2006.

In addition to the litigation discussed above, we are from time to time, subject to legal proceedings and claims arising in the ordinary course of business, some of which may be covered in whole or in part by insurance.

Table of Contents**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

The following discussion should be read in conjunction with the Consolidated Financial Statements and the related notes included in Item 1 of this Form 10-Q. The following discussion contains forward-looking statements which involve risks and uncertainties. When used in this Form 10-Q, terms such as anticipates, believes, continue, could, estimates, expects, intends, may, plans, potential, predicts, should, or will or the negative of those terms or other comparable terms are intended to identify such forward-looking statements. Such statements, which include statements concerning product sales, research and development expenses, selling, general and administrative expenses, additional financings and additional losses, are subject to known and unknown risks and uncertainties, including, but not limited to, those discussed below and elsewhere in this Form 10-Q and our Annual Report on Form 10-K/A, particularly in Factors Affecting Our Operating Results and Financial Condition, that could cause actual results, levels of activity, performance or achievement to differ significantly from those projected. Although we believe that expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We will not update any of the forward-looking statements after the date of this Form 10-Q to conform these statements to actual results or changes in our expectations. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this Form 10-Q.

OVERVIEW

We develop, acquire and commercialize novel treatments for cancer. Our goal is to build a leading biopharmaceutical company with a diversified portfolio of proprietary oncology drugs. Our research, development, acquisition and in-licensing activities concentrate on identifying and developing new, less toxic and more effective ways to treat cancer.

We are developing XYOTAX, paclitaxel poliglumex, for the treatment of non-small cell lung cancer, or NSCLC, and ovarian cancer. Our STELLAR 2, 3, and 4, phase III clinical studies for XYOTAX did not meet their primary endpoints of superior overall survival. However, we believe a pooled analysis of STELLAR 3 and 4 demonstrates a statistically significant survival advantage among women receiving XYOTAX when compared to women or men receiving standard chemotherapy. A survival advantage for women over men was also demonstrated in a first-line phase II clinical trial of XYOTAX and carboplatin, known as the PGT202 trial, supporting the potential benefit observed in the STELLAR first-line trials. We believe the lack of safe and effective treatments for women with advanced first-line NSCLC who are performance status 2, or PS2, represents an unmet medical need. In December, 2005, we initiated an additional study, known as the PIONEER, or PGT305, study, for XYOTAX as first-line monotherapy in PS2 women with NSCLC. In February 2006, the U.S. Food and Drug Administration, or FDA, confirmed that XYOTAX qualifies for fast track designation for the treatment of PS2 women with first-line advanced NSCLC. In a meeting with the FDA in the first half of 2006, we agreed on a new drug application, or NDA, submission route for XYOTAX for women with advanced NSCLC who are PS2. The FDA agreed to review an NDA submission based on interim results of the PIONEER trial with the results of the STELLAR 3 and 4 trials to support the filing. Based on this feedback, if the PIONEER trial meets its pre-specified interim endpoint, CTI plans to submit an NDA in the first half of 2007 and would request a priority (six month) review based on the fast track designation, instead of the standard (ten month) review as previously planned. We may be unable to submit an NDA as discussed if the PIONEER trial does not meet its pre-specified interim endpoint. Based on discussions with Scientific Advice Working Party, or SAWP, of the European Medicines Agency, or EMEA, we plan to submit a marketing authorization application, or MAA, in Europe based on a non inferior survival and improved side effect profile. The discussions with the SAWP focused on using the STELLAR 4 study as primary evidence of non-inferiority and the STELLAR 3 study as supportive.

We are developing pixantrone, a novel anthracycline derivative, for the treatment of non-Hodgkin's lymphoma, or NHL. An interim analysis of our ongoing phase III study of pixantrone was performed by the independent Data Monitoring Committee in the third quarter of 2006. Based on their review, the study will continue. Another interim analysis of the study will be performed on approximately 100 patients and is targeted for the first half of 2007.

Table of Contents

We also are developing CT-2106, polyglutamate camptothecin, which is in the phase II component of a phase I/II trial in combination with 5FU/LV for the treatment of colorectal cancer relapsing following FOLFOX therapy and in a phase II trial in ovarian cancer.

As of June 30, 2006, we had incurred aggregate net losses of approximately \$897.7 million since inception. We expect to continue to incur additional operating losses for at least the next several years.

Critical Accounting Estimates

Management makes certain judgments and uses certain estimates and assumptions when applying accounting principles generally accepted in the United States in the preparation of our consolidated financial statements. We evaluate our estimates and judgments on an on-going basis and base our estimates on historical experience and on assumptions that we believe to be reasonable under the circumstances. Our experience and assumptions form the basis for our judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may vary from what we anticipate and different assumptions or estimates about the future could change our reported results. We believe the following accounting estimates are the most critical to us, in that they are important to the portrayal of our consolidated financial statements and require our most difficult, subjective or complex judgments in the preparation of our consolidated financial statements.

License and Contract Revenue

We may generate revenue from technology licenses, collaborative research and development arrangements, cost reimbursement contracts and research grants. Revenue under technology licenses and collaborative agreements typically consists of nonrefundable and/or guaranteed technology license fees, collaborative research funding, and various milestone and future product royalty or profit-sharing payments.

Revenue associated with up-front license fees and research and development funding payments under collaborative agreements is recognized ratably over the relevant periods specified in the agreement, generally the research and development period. If the time period is not defined in the agreement, we calculate the revenue recognition period based on our current estimate of the research and development period considering experience with similar projects, level of effort and the stage of development. Should there be a change in our estimate of the research and development period, we will revise the term over which the initial payment is recognized. Revenue from substantive at-risk milestones and future product royalties is recognized as earned based on the completion of the milestones and product sales, as defined in the respective agreements. Revenue under cost reimbursement contracts and research grants is recognized as the related costs are incurred. Payments received in advance of recognition as revenue are recorded as deferred revenue.

We evaluate multiple element arrangements pursuant to Emerging Issues Task Force, or EITF, 00-21, *Revenue Arrangements with Multiple Deliverables*. For multiple element arrangements that have continuing performance obligations, we recognize contract, milestone or license fees together with any up-front payments over the term of the arrangement as we complete our performance obligation, unless the delivered technology has stand alone value to the customer and there is objective, reliable evidence of fair value of the undelivered element in the arrangement. Additionally, pursuant to the guidance of Securities and Exchange Commission Staff Accounting Bulletin 104, or SAB 104, unless evidence suggests otherwise, revenue from consideration received is recognized on a straight-line basis over the expected term of the arrangement.

Impairment of Long-lived Assets

We review our long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows to the recorded value of the asset. If an impairment is indicated, the asset is written down to its estimated fair value based on quoted fair market values.

Table of Contents

Valuation of Goodwill

In accordance with Statement of Financial Accounting Standards, or SFAS, No. 142, *Goodwill and Other Intangible Assets*, we review goodwill for impairment annually and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Goodwill is tested for impairment by comparing the fair value of our single reporting unit to its carrying value. Our estimate of fair value is based on our current market capitalization. If the implied fair value of goodwill is less than its carrying value, an impairment charge would be recorded.

Derivatives Embedded in Certain Debt Securities

We evaluate financial instruments for freestanding or embedded derivatives in accordance with Statement of Financial Accounting Standards, or SFAS, No. 133, *Accounting for Derivative Instruments and Hedging Activities*, and related guidance. Derivative instruments are recorded at fair value with changes in value recognized in the period of change.

Our 6.75% convertible senior notes, or 6.75% notes, and our 7.5% convertible senior notes, or 7.5% notes, contain certain features providing for payments in cash or common stock to be made in the event of certain conversions or repurchases of the debt. In the event of any conversion of our 6.75% notes to common stock, the feature calls for make-whole payments equal to the interest on the debt over its term less any amounts paid prior to the date of the conversion. Our 7.5% notes include a feature that calls for make-whole payments in the event of automatic conversion or if the holder requires us to repurchase the notes upon certain non-stock changes in control. This payment is equal to \$225 per \$1,000 principal amount of the notes less any interest amounts paid prior to the date of conversion or repurchase.

These make-whole features represent embedded derivatives which are required to be accounted for separately from the related debt securities. The fair value of the derivative for the 6.75% notes is calculated based on a discounted cash flow model. The fair value of the derivative related to the 7.5% notes is calculated using a Monte Carlo simulation model that incorporates factors such as the current price of our common stock, its volatility, and time to expiration of the make-whole feature. Changes in the estimated fair value of the liabilities are included in *gain on derivative liabilities* and will be required until the relevant feature expires or all of the relevant notes are converted or repurchased.

Restructuring Charges

We have recorded charges in connection with our restructuring activities, including estimates pertaining to employee separation costs, the related abandonment of excess facilities and impairment of fixed assets, and certain contract termination costs. Restructuring charges are recorded in accordance with SFAS 146, *Accounting for Costs Associated with Exit or Disposal Activities*. The recognition of restructuring charges requires management to make certain judgments regarding the nature, timing and amount associated with the planned restructuring activities. At the end of each reporting period, we evaluate the appropriateness of the remaining accrued balances.

Stock-Based Compensation Expense

On January 1, 2006, we adopted SFAS 123(R), *Share-Based Payment (Revised 2004)*, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options, share awards, and employee stock purchases related to the Employee Stock Purchase Plan, or employee stock purchases, based on estimated fair values. SFAS 123(R) supersedes our previous accounting under Accounting Principles Board Opinion, or APB, No. 25, *Accounting for Stock Issued to Employees*, for periods beginning in fiscal 2005. In March 2005, the Securities and Exchange Commission issued Staff Accounting Bulletin, or SAB, No. 107 relating to SFAS 123(R). We have applied the provisions of SAB 107 in our adoption of SFAS 123(R).

Table of Contents

We adopted SFAS 123(R) using the modified prospective transition method, which requires the application of the accounting standard as of January 1, 2006, the first day of our fiscal year 2006. Our Condensed Consolidated Financial Statements as of and for the three and six months ended June 30, 2006 reflect the impact of SFAS 123(R). In accordance with the modified prospective transition method, our Condensed Consolidated Financial Statements for prior periods have not been restated to reflect, and do not include, the impact of SFAS 123(R).

As a result of adopting SFAS 123(R), our net loss was \$2.5 million higher and our basic and diluted net loss per share was \$0.03 higher than if we had continued to account for share-based compensation under APB No. 25 for the six months ended June 30, 2006.

As of June 30, 2006, the total remaining unrecognized compensation cost related to unvested stock options and share awards amounted to \$2.4 million, which will be amortized over the weighted-average remaining requisite service period of 1.0 years. This amount does not include unrecognized compensation cost related to 650,000 shares of contingent share awards granted during 2005 and 180,000 contingent stock options granted in June 2006 which will vest upon the achievement of certain performance goals.

The risk-free interest rate used in the Black-Scholes valuation method is based on the implied yield currently available in U.S. Treasury securities at maturity with an equivalent term. We have not declared or paid any dividends and do not currently expect to do so in the future. The expected term of options represents the period that our stock-based awards are expected to be outstanding and was determined based on historical weighted average holding periods and projected holding periods for the remaining unexercised shares. Consideration was given to the contractual terms of our stock-based awards, vesting schedules and expectations of future employee behavior. Expected volatility is based on the annualized daily historical volatility, including consideration of the implied volatility and market prices of traded options for comparable entities within our industry.

Our stock price volatility and option lives involve management's best estimates, both of which impact the fair value of the option calculated under the Black-Scholes methodology and, ultimately, the expense that will be recognized over the life of the option. SFAS 123(R) also requires that we recognize compensation expense for only the portion of options expected to vest. Therefore, we applied an estimated forfeiture rate that we derived from historical employee termination behavior. If the actual number of forfeitures differs from our estimates, additional adjustments to compensation expense may be required in future periods.

RESULTS OF OPERATIONS

Three months ended June 30, 2006 and 2005.

Product sales. TRISENOX was, prior to its divestiture to Cephalon in July 2005, our commercial product approved by the FDA, EMEA, and the Japanese Ministry of Health, or JMH, to treat patients with relapsed or refractory acute promyelocytic leukemia, or APL. As a result of the divestiture, there were no product sales for the three months ended June 30, 2006. We recorded net product sales of approximately \$7.4 million for TRISENOX for the three months ended June 30, 2005.

License and contract revenue. In October 2001, we entered into a licensing agreement with Chugai Pharmaceutical Co., Ltd., or Chugai, for the development and commercialization of XYOTAX. This agreement granted an exclusive license to Chugai to develop and commercialize XYOTAX in several Asian markets. Upon execution of the Chugai agreement, we received a \$3.0 million initial payment, which we recorded as deferred revenue and which was being recognized as revenue over the estimated development period of approximately seven years on a straight-line basis. As of December 31, 2005, we recognized the remaining deferred revenue related to this initial payment in anticipation of the termination of our agreement with Chugai which occurred in March 2006.

License and contract revenue for the three months ended June 30, 2006 represents recognition of revenue deferred from the sale of Lisofylline material to Diakine. For the three month period ended June 30, 2005, we recognized approximately \$0.1 million of license and contract revenue primarily relating to the amortization of the initial payments from Chugai.

Table of Contents

Cost of product sold. There was no cost of product sold for the three months ended June 30, 2006 due to the divestiture of TRISENOX to Cephalon on July 18, 2005. The cost of product sold during the three months ended June 30, 2005 was approximately \$0.2 million. Cost of product sold consisted primarily of manufacturing costs, royalties paid on product sales, and allowances for excess inventory that may expire and become unsaleable.

Research and development expenses. Our research and development expenses for compounds under development and discovery research are as follows (in thousands):

| | Three Months Ended | |
|---|--------------------|-----------|
| | June 30, 2006 | 2005 |
| Compounds under development: | | |
| XYOTAX | \$ 5,490 | \$ 6,245 |
| Pixantrone | 2,498 | 1,739 |
| TRISENOX | | 1,455 |
| Other compounds | 75 | 497 |
| Operating expenses | 6,707 | 8,486 |
| Discovery research | 394 | 1,757 |
| Total research and development expenses | \$ 15,164 | \$ 20,179 |

Costs for compounds under development include external direct expenses such as principal investigator fees, clinical research organization charges and contract manufacturing fees incurred for preclinical, clinical, manufacturing and regulatory activities associated with preparing the compounds for submissions of new drug applications or similar regulatory filings to the FDA, EMEA or other regulatory agencies outside the United States and Europe. Operating costs include our personnel and occupancy expenses associated with developing these compounds. Discovery research costs include primarily personnel, occupancy and laboratory expenses associated with the discovery and identification of new drug targets and lead compounds. We do not allocate operating costs to the individual compounds under development as our accounting system does not track these costs by individual compound. As a result, we are not able to capture the total cost of each compound. Direct external costs incurred to date for XYOTAX, TRISENOX and pixantrone are approximately \$179.3 million, \$29.1 million and \$18.8 million, respectively. Costs for pixantrone prior to our merger with Novuspharma S.p.A, a public pharmaceutical company located in Italy, or CTI-Europe, in January 2004 are excluded from this amount.

Research and development expenses decreased to approximately \$15.2 million for the three months ended June 30, 2006, from approximately \$20.2 million for the three months ended June 30, 2005. Costs for our XYOTAX program decreased primarily due to a \$1.7 million write-down of our paclitaxel supply to its estimated fair value in the second quarter of 2005 and a decrease related to our STELLAR phase III trials which were winding down during the three months ended June 30, 2005. These costs were partially offset by an increase in clinical trial costs for our PIONEER study which was initiated in the fourth quarter of 2005 as well as an increase in manufacturing costs. Pixantrone costs increased due to an increase in clinical trial expenses, attributable to increased patient enrollment and sites for our phase II and III clinical trials. TRISENOX costs decreased due to the divestiture of TRISENOX to Cephalon. Costs for other compounds decreased due to slower new patient enrollment in our CT-2106 trials in 2006 as compared to 2005. Operating costs decreased primarily due to a reduction in our headcount resulting from our restructuring activities in 2005. Discovery research costs decreased primarily as a result of decreased personnel and other costs due to a reduction in programs.

Our lead drug candidates, XYOTAX and pixantrone are currently in clinical trials. Many drugs in human clinical trials fail to demonstrate the desired safety and efficacy characteristics. Even if our drugs progress successfully through initial human testing, they may fail in later stages of development. A number of companies in the pharmaceutical industry, including us, have suffered significant setbacks in advanced clinical trials, even after reporting promising results in earlier trials. Regulatory agencies, including the FDA and EMEA, regulate many aspects of a product candidate's life cycle, including research and development and preclinical and clinical testing. We or regulatory authorities may suspend clinical trials at any time on the basis that the participants are being exposed to unacceptable health risks. Completion of clinical trials depends on, among other things, the number of patients available for enrollment in a particular trial, which is a function of many factors, including the availability

Table of Contents

and proximity of patients with the relevant condition. We rely on third parties to conduct clinical trials, which may result in delays or failure to complete trials if the third parties fail to perform or meet applicable standards. Many of our drug candidates are still in research and preclinical development, which means that they have not yet been tested on humans. We will need to commit significant time and resources to develop these and additional product candidates.

Our products will be successful only if:

our product candidates are developed to a stage that will enable us to commercialize them or sell related marketing rights to pharmaceutical companies;

we are able to commercialize product candidates in clinical development or sell the marketing rights to third parties; and

our product candidates, if developed, are approved.

We will be dependent on the successful completion of these goals in order to generate revenues. The failure to generate such revenues may preclude us from continuing our research and development of these and other product candidates. We also enter into collaboration agreements for the development and commercialization of our product candidates. We cannot control the amount and timing of resources our collaborators devote to product candidates, which may also result in delays in the development or marketing of products.

Because of these risks and uncertainties, we cannot accurately predict when or whether we will successfully complete the development of our product candidates or the ultimate product development cost. We reported XYOTAX STELLAR 3 clinical trial results in March 2005 and STELLAR 2 and 4 results in May 2005, all of which missed their primary endpoints of superior overall survival. We are targeting submission of an NDA for XYOTAX in the first half of 2007, depending on the duration of the review cycle, timing, and assuming positive results of the interim analysis of the PIONEER trial, with a U.S. XYOTAX approval targeted in late 2007 and launch shortly thereafter. Approval in the EU would be targeted approximately 15 months following the submission of an MAA, which is planned for the first half of 2007.

We may not generate significant revenue from the sale of commercial drugs for at least the next couple of years, if ever. Without revenue generated from commercial sales, we anticipate that funding to support our ongoing research, development and general operations will primarily come from public or private debt or equity financings, collaborations, milestones and licensing opportunities from current or future collaborators.

Selling, general and administrative expenses. Selling, general and administrative expenses decreased to approximately \$8.3 million for the three months ended June 30, 2006, from approximately \$17.6 million for the three months ended June 30, 2005. This decrease is primarily attributed to a \$6.4 million decrease in our sales and marketing expenses related to reduced commercialization efforts and headcount due to the divestiture of TRISENOX to Cephalon in the third quarter of 2005, a \$1.8 million decrease in operating expenses primarily related to decreased compensation and benefits, occupancy and other expenses resulting from a reduction in headcount, and a \$1.3 million decrease in corporate development expenses primarily due to a decrease in aircraft operating costs resulting from the termination of our aircraft operating lease in the fourth quarter of 2005. These decreases were offset by a \$0.2 million increase in stock-based compensation expense primarily related to the implementation of SFAS 123(R). Corporate development expenses include certain legal expenses, business development activities, corporate sponsorships and charitable contributions, costs related to operating our aircraft, and our corporate communications programs.

We expect selling, general and administrative expenses to continue to decrease in 2006 as compared to 2005 due to the divestiture of TRISENOX to Cephalon as well as the termination of our aircraft lease in 2005. In the event that we are able to move forward with the commercialization of XYOTAX, our sales and marketing expenses would then increase.

Table of Contents

Amortization of purchased intangibles. Amortization for the three months ended June 30, 2006 decreased slightly as compared to the three months ended June 30, 2005, due to a write-down of our assembled workforce asset in December 2005.

Restructuring charges and related asset impairments. In 2005, we announced plans to reduce our workforce through selected layoffs of employees as part of our cost savings initiative in an effort to reduce costs and conserve capital in anticipation of an NDA filing and potential launch of XYOTAX. In conjunction with our workforce reduction, we vacated a portion of our laboratory and office facilities. Restructuring activities and asset impairments for the three months ended June 30, 2006 primarily relate to adjustments due to a change in our estimate of the timing and amount of cash flows related to our excess facilities as well as adjustments due to the passage of time. Restructuring activities and asset impairments for the three months ended June 30, 2005 included \$1.5 million due to a significant reduction in workforce and \$0.5 million in write-downs of tangible assets resulting from this workforce reduction.

Investment and other income. Investment and other income for the quarter ended June 30, 2006 and 2005 was approximately \$0.7 million and \$0.4 million, respectively. This increase is due to higher prevailing interest rates on our investments during the quarter ended June 30, 2006 compared to the quarter ended June 30, 2005.

Interest expense. Interest expense increased to approximately \$4.7 million for the three months ended June 30, 2006 from approximately \$4.0 million for the three months ended June 30, 2005. This increase is due to \$1.1 million in accretion of the debt discount on our 6.75% and 7.5% notes, interest expense of \$0.9 million related to these notes and \$0.9 million in accelerated amortization of debt issuance costs primarily due to conversions of these notes. These increases were partially offset by a decrease of \$1.3 million related to our royalty interest financing agreement entered into with PharmaBio in December 2004 and terminated in July 2005 in connection with the divestiture of TRISENOX and a decrease of \$0.8 million in interest expense on our 4.0% senior subordinated and 5.75% subordinated and senior subordinated notes due to the retirement and exchange of a portion of these notes in the fourth quarter of 2005 and first half of 2006.

Foreign exchange gain. The increase in exchange gain for the three months ended June 30, 2006 is due to fluctuations in foreign currency exchange rates, primarily related to payables denominated in foreign currencies.

Make-whole interest expense. Make-whole interest expense of \$4.4 million is related to payments made upon the conversion of \$8.9 million of our 6.75% notes and \$7.4 million of our 7.5% notes during the three months ended June 30, 2006.

Gain on derivative liabilities. The gain on the derivative liabilities of \$2.7 million for the three months ended June 30, 2006 represents the change in the estimated fair value of our derivative liabilities related to the interest make-whole provisions on our 6.75% and 7.5% notes of \$0.6 million and \$2.1 million, respectively.

Gain on exchange of convertible notes. We recorded a gain of \$8.0 million due to the extinguishment of approximately \$40.7 million aggregate principal amount of our 5.75% convertible senior subordinated and convertible subordinated notes in exchange for approximately \$33.2 million aggregate principal amount of our 7.5% notes. The gain is net of accrued interest of \$0.9 million and issuance costs of \$0.4 million attributable to the exchanged notes.

Six months ended June 30, 2006 and 2005.

Product sales. As a result of the divestiture of Trisenox to Cephalon, there were no product sales for the six months ended June 30, 2006. We recorded net product sales of approximately \$13.4 million for TRISENOX for the six months ended June 30, 2005.

License and contract revenue. License and contract revenue for the six months ended June 30, 2006 represents recognition of revenue deferred from the sale of Lisofylline material to Diakine. For the six month period ended

Table of Contents

June 30, 2005, we recognized approximately \$0.2 million of license and contract revenue primarily relating to the amortization of the initial payments from Chugai.

Cost of product sold. There was no cost of product sold for the six months ended June 30, 2006 due to the divestiture of TRISENOX to Cephalon on July 18, 2005. The cost of product sold during the six months ended June 30, 2005 was approximately \$0.5 million. Cost of product sold consisted primarily of manufacturing costs, royalties paid on product sales, and allowances for excess inventory that may expire and become unsaleable.

Research and development expenses. Our research and development expenses for compounds under development and discovery research are as follows (in thousands):

| | Six Months Ended | |
|---|------------------|-----------|
| | June 30, 2006 | 2005 |
| Compounds under development: | | |
| XYOTAX | \$ 11,584 | \$ 12,073 |
| Pixantrone | 5,291 | 3,165 |
| TRISENOX | | 3,539 |
| Other compounds | 555 | 1,116 |
| Operating expenses | 12,710 | 17,955 |
| Discovery research | 788 | 4,394 |
| Total research and development expenses | \$ 30,928 | \$ 42,242 |

Research and development expenses decreased to approximately \$30.9 million for the six months ended June 30, 2006, from approximately \$42.2 million for the six months ended June 30, 2005. Costs for our XYOTAX program decreased primarily due to a \$1.7 million write-down of our paclitaxel supply to its estimated fair value in the second quarter of 2005 and other decreases in manufacturing costs offset by an increase in clinical activity in 2006 primarily related to the initiation of our PIONEER trial in the fourth quarter of 2005. Pixantrone costs increased due to an increase in clinical trial expenses, attributable to increased patient enrollment and sites for our phase II and III clinical trials. TRISENOX costs decreased due to the divestiture of TRISENOX to Cephalon. Costs for other compounds decreased due to slower patient enrollment in our CT-2106 trials in 2006 as compared to 2005. Operating costs decreased primarily due to a reduction in our headcount resulting from our restructuring activities in 2005. Discovery research costs decreased primarily as a result of decreased personnel and other costs due to a reduction in programs.

Selling, general and administrative expenses. Selling, general and administrative expenses decreased to approximately \$18.4 million for the six months ended June 30, 2006, from approximately \$37.0 million for the six months ended June 30, 2005. This decrease is primarily attributed to a \$13.3 million decrease in our sales and marketing expenses related to reduced commercialization efforts and headcount due to the divestiture of TRISENOX to Cephalon in the third quarter of 2005, a \$3.1 million decrease in operating expenses primarily related to decreased compensation and benefit, occupancy and other expenses resulting from a reduction in headcount, and a \$2.6 million decrease in corporate development expenses, primarily due to a decrease in aircraft operating costs resulting from the termination of our aircraft operating lease in the fourth quarter of 2005, and. These decreases were offset by a \$0.4 million increase in stock-based compensation expense primarily related to the implementation of SFAS 123(R).

Amortization of purchased intangibles. Amortization for the six months ended June 30, 2006 decreased to approximately \$0.4 million from approximately \$0.5 million for the six months ended June 30, 2005, due to a write-down of our assembled workforce asset in December 2005.

Restructuring charges and related asset impairments. Restructuring activities and asset impairments for the six months ended June 30, 2006 primarily relate to adjustments due to a change in our estimate of the timing and amount of cash flows related to our excess facilities as well as adjustments due to the passage of time. Restructuring activities and asset impairments for the six months ended June 30, 2005 included \$1.5 million due to a significant reduction in workforce and \$0.5 million in write-downs of tangible assets resulting from this workforce reduction.

Table of Contents

Investment and other income. Investment and other income for the six months ended June 30, 2006 and 2005 was approximately \$1.2 million and \$0.9 million, respectively. This increase is due to higher prevailing interest rates on our investments during the six months ended June 30, 2006 compared to the six months ended June 30, 2005.

Interest expense. Interest expense increased to approximately \$13.3 million for the six months ended June 30, 2006 from approximately \$7.9 million for the six months ended June 30, 2005. This increase is due to \$4.5 million in accretion of the debt discount on our 6.75% and 7.5% notes, accelerated amortization of debt issuance costs of \$4.3 million primarily related to conversions of these notes, and interest expense of \$0.7 million related to our 7.5% notes. These increases were offset by a decrease of \$2.5 million related to our royalty interest financing agreement entered into with PharmaBio in December 2004 and terminated in July 2005 in connection with the divestiture of TRISENOX and a decrease of \$1.5 million in interest expense for our convertible notes due to the retirement, exchange or conversion of a portion of these notes in the fourth quarter of 2005 and first half of 2006.

Foreign exchange gain. The increase in exchange gain for the six months ended June 30, 2006 is due to fluctuations in foreign currency exchange rates, primarily related to payables denominated in foreign currencies.

Make-whole interest expense. Make-whole interest expense of \$24.5 million is related to payments made upon the conversion of \$68.6 million of our 6.75% notes and \$7.4 million of our 7.5% notes during the six months ended June 30, 2006.

Gain on derivative liabilities. The gain on the derivative liabilities of \$6.1 million for the six months ended June 30, 2006 represents the change in the estimated fair value of our derivative liabilities related to the interest make-whole provisions on our 6.75% and 7.5% notes of \$4.0 million and \$2.1 million, respectively.

Gain on exchange of convertible notes. We recorded a gain of \$8.0 million due to the extinguishment of approximately \$40.7 million aggregate principal amount of our 5.75% convertible senior subordinated and convertible subordinated notes in exchange for approximately \$33.2 million aggregate principal amount of our 7.5% notes. The gain is net of accrued interest of \$0.9 million and issuance costs of \$0.4 million attributable to the exchanged notes.

Settlement expense. Settlement expense for the six months ended June 30, 2006 relates to the amount paid under the settlement of our dispute with Micromet AG in May 2006 and is net of payables previously due to Micromet.

LIQUIDITY AND CAPITAL RESOURCES

As of June 30, 2006, we had approximately \$48.2 million in cash and cash equivalents, restricted cash, securities available-for-sale and interest receivable.

Net cash used in operating activities increased to approximately \$73.8 million during the six months ended June 30, 2006, compared to approximately \$73.0 million for the same period during 2005 primarily due to an increase in our net loss. For the six months ended June 30, 2006, our net loss included \$24.5 million in make-whole interest payments related to conversions of our 6.75% and 7.5% notes.

Net cash provided by investing activities totaled approximately \$1.7 million during the six months ended June 30, 2006, compared to net cash used of approximately \$3.3 million for the same period during 2005. Net cash provided by or used in investing activities for the two periods was primarily due to proceeds from sales and maturities of securities available-for-sale and sales of property and equipment, offset by purchases of securities available-for-sale and property and equipment.

Net cash provided by financing activities totaled approximately \$53.2 million during the six months ended June 30, 2006, compared to net cash used in financing activities of approximately \$0.5 million for the same period during 2005. The cash provided by financing activities for the six months ended June 30, 2006 was primarily due to net proceeds received from the issuance of our 7.5% notes as well as restricted cash related to the issuance of our 6.75%

Table of Contents

convertible senior notes that was released from escrow upon conversion of a portion of these notes. Cash used in investing activities for the six months ended June 30, 2005 primarily relates to the repayment of long-term obligations.

We expect to generate losses from operations for at least the next several years due to research and development costs for XYOTAX, pixantrone and CT-2106.

The financial statements have been prepared on a basis of a going concern which contemplates realization of assets and satisfaction of liabilities in the normal course of business. We expect that our existing cash, cash equivalents, securities available-for-sale and interest receivable will not be sufficient to fund our operations for the next 12 months. Accordingly, we will need to raise additional funds and are currently exploring alternative sources of equity or debt financing. Additional funding may not be available on favorable terms or at all. If we are unable to raise additional capital in the near term, we have developed a plan to further curtail operations significantly, by delaying, modifying, or canceling selected aspects for research and development programs related to XYOTAX, pixantrone and other products we may be developing. The plan contains reductions in operating expenditures related to certain research and development and general and administrative activities including compensation and benefits, corporate costs and clinical trial costs, which are designed to allow the company to continue to operate on a going concern basis.

Periodically, we may receive certain grants and subsidized loans from the Italian government and the EU through CTI-Europe. However, to date such grants have not been significant and we may not receive such funding because the grants and subsidies are awarded at the discretion of the relevant authorities. In addition, our future capital requirements will depend on many factors, including:

results of our clinical trials;

success in acquiring or divesting products, technologies or businesses;

progress in and scope of our research and development activities; and

competitive market developments.

Future capital requirements will also depend on the extent to which we acquire or invest in businesses, products and technologies or sell or license our products to others. We will require additional financing and such financing may not be available when needed or, if available, we may not be able to obtain it on terms favorable to us or to our shareholders. Insufficient funds may require us to delay, scale back or eliminate some or all of our research and development programs, or may adversely affect our ability to operate as a going concern. If additional funds are raised by issuing equity securities, substantial dilution to existing shareholders may result.

Table of Contents

The following table includes information relating to our contractual obligations as of June 30, 2006 (in thousands):

| Contractual Obligations | Payments Due by Period | | | | |
|---|------------------------|-----------|-----------|------------|---------------|
| | Total | 1 Year | 2-3 Years | 4-5 Years | After 5 Years |
| 7.5% Convertible senior notes (1) | \$ 58,937 | \$ | \$ | \$ 58,937 | \$ |
| 6.75% Convertible senior notes (2) | 7,700 | | | 7,700 | |
| 5.75% Convertible senior subordinated notes (3) | 27,407 | | 27,407 | | |
| 4.0% Convertible senior subordinated notes (4) | 55,150 | | | 55,150 | |
| 5.75% Convertible subordinated notes (5) | 28,490 | | 28,490 | | |
| Interest on convertible notes (6) | 38,721 | 10,360 | 17,372 | 10,989 | |
| Operating leases: | | | | | |
| Facilities | 29,453 | 8,383 | 9,352 | 7,582 | 4,136 |
| Long term obligations (7) | 2,675 | 238 | 767 | 939 | 731 |
| | \$ 248,533 | \$ 18,981 | \$ 83,388 | \$ 141,297 | \$ 4,867 |

- (1) The 7.5% convertible senior notes are convertible into shares of CTI common stock at a conversion rate of 478.519 shares of common stock per \$1,000 principal amount of the notes, which is equivalent to a conversion price of approximately \$2.09 per share.
- (2) The 6.75% convertible senior notes are convertible into shares of CTI common stock at a conversion rate of 380.37 shares of common stock per \$1,000 principal amount of the notes, which is equivalent to a conversion price of approximately \$2.63 per share.
- (3) The 5.75% convertible senior subordinated notes are convertible into shares of CTI common stock at a conversion rate of 100 shares of common stock per \$1,000 principal amount of the notes, which is equivalent to a conversion price of \$10.00 per share.
- (4) The 4.0% convertible senior subordinated notes are convertible into shares of CTI common stock at a conversion rate of 74.0741 shares of common stock per \$1,000 principal amount of the notes, which is equivalent to a conversion price of approximately \$13.50 per share.
- (5) The 5.75% convertible subordinated notes are convertible into shares of CTI common stock at a conversion rate of 29.4118 shares of common stock per \$1,000 principal amount of the notes, which is equivalent to a conversion price of approximately \$34.00 per share.
- (6) As of June 30, 2006, we have made \$25.6 million in cumulative make-whole interest payments related to the early conversions of \$71.6 million of our 6.75% convertible senior notes and \$7.4 million of our 7.5% convertible senior notes.
- (7) Long-term debt does not include \$4.9 million related to excess facilities charges and \$1.1 million recorded as a long-term obligation for benefits owed to our Italian employees pursuant to Italian Law. The timing of the payments related to this obligation is unknown as the benefit is paid upon an employees' separation from the Company.

The remaining amount of milestone payments we may be required to pay pursuant to the amended agreement with PG-TXL Company L.P. is \$14.9 million, \$3.4 million of which may be triggered in 2007 if we are successful with our current plans for registrations with the FDA and EMEA.

Table of Contents**Item 3. Quantitative and Qualitative Disclosures About Market Risk***Interest Rate Market Risk*

We are exposed to market risk related to changes in interest rates that could adversely affect the value of our investments. We maintain a short-term investment portfolio consisting of interest bearing securities with an average maturity of less than one year. These securities are classified as available-for-sale. These securities are interest bearing and thus subject to interest rate risk and will fall in value if market interest rates increase. Since we generally hold our fixed income investments until maturity, we do not expect our operating results or cash flows to be affected significantly by a sudden change in market interest rates related to our securities portfolio. The fair value of our securities available-for-sale at June 30, 2006 and December 31, 2005 was \$17.2 million and \$18.9 million, respectively. A one percent change in interest rates would not significantly impact the fair value of our securities available-for-sale as of June 30, 2006 and December 31, 2005, respectively.

Foreign Exchange Market Risk

We are exposed to risks associated with foreign currency transactions insofar as we use U.S. dollars to make contract payments denominated in euros or vice versa. As the net positions of our unhedged foreign currency transactions fluctuate, our earnings might be negatively affected. In addition, we are exposed to risks associated with the translation of euro-denominated financial results and accounts into U.S. dollars. Although our reporting currency remains the U.S. dollar, a significant portion of our consolidated costs now arise in euros, which we translate into U.S. dollars for purposes of financial reporting, based on exchange rates prevailing during the applicable reporting period. In addition, the reported carrying value of our euro-denominated assets and liabilities will be affected by fluctuations in the value of the U.S. dollar as compared to the euro. Accordingly, changes in the value of the U.S. dollar relative to the euro might have an adverse effect on our reported results of operations and financial condition, and fluctuations in exchange rates might harm our reported results and accounts from period to period.

We have foreign exchange risk related to foreign-denominated cash, restricted cash, cash equivalents and interest receivable (foreign funds). Based on the balance of foreign funds at June 30, 2006 of \$3.6 million, an assumed 5%, 10% and 20% negative currency exchange movement would result in fair value declines of \$0.2 million, \$0.4 million and \$0.7 million.

Item 4. Controls and Procedures**(a) Evaluation of Disclosure Controls and Procedures**

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in its Securities Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to the our management to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as our controls are designed to do, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Previously, our management, under the supervision and with the participation of the Company's Chief Executive Officer (CEO) and Chief Financial Officer (CFO), had evaluated the effectiveness of our disclosure controls and procedures as defined in SEC Rule 13a-15(e) as of the end of the period covered by this report. Management had concluded that our disclosure controls and procedures were effective to ensure that information we are required to disclose in reports that we file or submit under the Securities Exchange Act is communicated to management, including the CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure and is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms. However, in connection with the filing of this Amendment No. 1 to our quarterly report on Form 10-Q, our management, under the supervision and with the participation of the Company's CEO and CFO, reevaluated the effectiveness of our disclosure controls and procedures as of June 30, 2006, and concluded that due to the material weakness described below, we did not have effective disclosure controls and procedures relative to accounts payable and accrued expense balances as of June 30, 2006.

Description of Material Weakness

A material weakness is a control deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected. We identified that at June 30, 2006, we had a material weakness relative to the effectiveness of our internal control over financial reporting. Specifically, we did not maintain effective controls over the accuracy, presentation and disclosure of accounts payable and accrued expenses in conformity with generally accepted

Edgar Filing: CELL THERAPEUTICS INC - Form 10-Q/A

accounting principles, including, maintaining effective controls to ensure that these balances were accurate in CTI (Europe).

Remediation of Material Weakness

In an effort to remediate the material weakness described above, we are currently implementing enhanced procedures that are designed to help ensure that we will accurately record accounts payable and accrued expense balances in CTI (Europe). These enhanced procedures will provide for additional managerial oversight of accounts payable and accrued expense balances.

(b) Changes in Internal Control Over Financial Reporting

Except as described above, there have been no changes to our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

Other Financial Information

With respect to the unaudited condensed consolidated financial statements of Cell Therapeutics, Inc. for the six-month period ended June 30, 2006, included herein, Stonefield Josephson, Inc. (Stonefield Josephson) reported that they have applied limited procedures in accordance with professional standards for a review of such information. However, their report dated August 8, 2006 appearing below, states that they did not audit and they do not express an opinion on that unaudited financial information. Stonefield Josephson has not carried out any significant or additional audit tests beyond those which would have been necessary if their report had not been included. Accordingly, the degree of reliance on their report on such information should be restricted in light of the limited nature of the review procedures applied. Stonefield Josephson is not subject to the liability provisions of Section 11 of the Securities Act of 1933 (the Act) for their report on the unaudited condensed consolidated financial statements because that report is not a report or a part of a registration statement prepared or certified by Stonefield Josephson within the meaning of Sections 7 and 11 of the Act.

Report of Independent Registered Public Accounting Firm

Board of Directors and Shareholders

Cell Therapeutics, Inc.

We have reviewed the accompanying condensed consolidated balance sheet of Cell Therapeutics, Inc. as of June 30, 2006, and the related condensed consolidated statements of operations for the six months ended June 30, 2006 and condensed consolidated statements of cash flows for the six months ended June 30, 2006. These interim financial statements are the responsibility of the Company's management.

We conducted our review in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with generally accepted auditing standards, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material modifications that should be made to the accompanying financial statements for them to be in conformity with accounting principles generally accepted in the United States of America.

As discussed in Note 2, the accompanying condensed consolidated balance sheet as of June 30, 2006 and the related condensed consolidated statements of operations for the three and six months ended June 30, 2006 and condensed statement of cash flows for the six months ended June 30, 2006 have been restated.

We have previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet as of December 31, 2005, and the related consolidated statements of operations, shareholders' deficit, and cash flows for the year then ended (not presented herein); and in our report dated March 14, 2006, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of December 31, 2005, is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.

/s/ Stonefield Josephson, Inc.

Stonefield Josephson, Inc.

Los Angeles, California

August 8, 2006, except for Note 2, as to which the date is February 4, 2007

Table of Contents

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

On February 10, 2004, Micromet AG, or Micromet, a Munich, Germany-based company, filed complaints against CTI in the federal district court for the Western District in the State of Washington, asserting that CTI-Europe, formerly known as Novuspharma S.p.A., had purportedly breached a contract with Micromet for the development of MT-201, a fully human antibody targeting the EP-CAM molecule. The claims alleged that CTI-Europe failed to pay for certain milestones and development expenses owed under the contract. On February 23, 2004, CTI answered the complaint, denying the substance of the allegations and filed counterclaims for breach of contract and for rescission of the contract based on Micromet's misrepresentations and failures to disclose material information including preclinical trial tests which were determined to be invalid. On May 3, 2006, CTI and Micromet entered into a settlement and release regarding this lawsuit pursuant to which CTI paid Micromet approximately \$1.9 million in cash and the lawsuit was dismissed with prejudice.

Beginning in March 2005, a number of purported shareholder class actions, alleging violations of federal securities laws, were filed against CTI, James Bianco and Max Link. These actions have been consolidated in the United States District Court for the Western District of Washington. On November 7, 2005, the plaintiffs filed a Consolidated and Amended Class Action Complaint against CTI, James Bianco and Jack Singer. The Consolidated and Amended Complaint asserts claims arising under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder on behalf of a class of purchasers of common stock during the period from November 14, 2003 to March 7, 2005, or the Class Period. Plaintiffs alleged that the defendants violated federal securities laws by, among other things, making false statements of material facts and/or omitting to state material facts to make the statements not misleading in connection with the results of the Company's STELLAR clinical trials for its drug XYOTAX. On January 6, 2006, CTI filed a motion to dismiss this class action complaint. On May 4, 2006 the Court granted CTI's motion to dismiss this lawsuit with leave to the plaintiffs to amend. On June 8, 2006 the Court entered a dismissal of this lawsuit with prejudice.

On May 9, 2005, Terence Fernandes, a shareholder of CTI, filed a complaint in the Superior Court of the State of Washington, King County on behalf of CTI against members of CTI's board of directors. The shareholder derivative action alleges breaches of fiduciary duties, abuse of control, gross mismanagement, waste of corporate assets and unjust enrichment since June 7, 2004. The case now resides in the United States District Court for the Western District of Washington. On December 7, 2005, plaintiff filed an amended complaint and defendants filed a motion to dismiss on February 6, 2006, to which plaintiffs responded on March 10, 2006. Defendants filed a reply brief on April 10, 2006. On June 22, 2006 the Court granted CTI's motion to dismiss this lawsuit with leave to the plaintiffs to amend. The period of time for the plaintiffs to amend the complaint has tolled. On July 31, 2006 defendants filed a motion to dismiss this lawsuit with prejudice for the failure of the plaintiffs to amend the complaint. No estimate of possible loss or range of loss resulting from the lawsuit can be made at this time.

The United States Attorney's Office, or USAO, for the Western District of Washington is conducting an investigation into certain of CTI's business practices relating to TRISENOX. USAO's investigation relates to CTI's promotional practices relating to TRISENOX; its reporting of revenue relating to TRISENOX sales; and statements made by CTI representatives, and its expert third party reimbursement consultant, relating to the eligibility of TRISENOX for Medicare reimbursement when the drug was used to treat certain off-label indications. USAO has issued subpoenas to third parties relating to its investigation. CTI is fully cooperating with USAO (through the provision of documents and periodic meetings) and has not received a subpoena relating to the matter. Management cannot predict whether USAO will bring formal criminal enforcement proceedings (and USAO has not indicated that it will). Claims associated with the above-referenced as well as related conduct have been filed against the Company under seal on behalf of the government by a private party in a qui tam action. Based on information currently available to the Company, we believe that the USAO may recommend to the Department of Justice that the government intervene in the qui tam action, as is its right, and assume the conduct of this lawsuit. We believe that regardless of whether the government or the private party pursues this lawsuit that one of the primary claims that might be pursued would be that CTI violated the Federal False Claims Act by receiving reimbursement from Medicare for improper off-label use of Trisenox or otherwise ineligible sales of TRISENOX over the period ranging

Table of Contents

from October 2000 until TRISENOX disposition to Cephalon in July of 2005. During this period the Company utilized a third party reimbursement expert. The Company believes it has meritorious defenses to these claims. It is unclear to the Company under this theory what sales or portions thereof would be in question. Accordingly, CTI cannot provide an estimate of a possible loss or range of loss in connection with this investigation or lawsuit. Under the False Claims Act, damages can be trebled and separate fines imposed for each violation, if the government or the private party plaintiff were to prevail in this lawsuit it is likely that such an adverse judgment would have a material adverse effect on our financial position, liquidity and results of operations.

We have not recorded a reserve for any of the above matters as of June 30, 2006.

In addition to the litigation discussed above, we are from time to time, subject to legal proceedings and claims arising in the ordinary course of business, some of which may be covered in whole or in part by insurance.

Item 1A. Risk Factors Factors Affecting Our Operating Results and Financial Condition

We expect to continue to incur net losses, and we might never achieve profitability.

We were incorporated in 1991 and have incurred a net operating loss every year. As of June 30, 2006, we had an accumulated deficit of approximately \$897.7 million. We are pursuing regulatory approval for XYOTAX and will need to conduct research, development, testing and regulatory compliance activities expenses which, together with projected general and administrative expenses, will result in operating losses for the foreseeable future. We may never become profitable, even if we are able to commercialize products currently in development or otherwise.

We have a substantial amount of debt.

We have a substantial amount of debt outstanding, and our annual interest expense with respect to our debt is significant. Unless we generate substantial sales from one of our potential products or raise substantial additional capital, we may not be able to repay this debt or the interest, liquidated damages or other payments with respect to our debt. Prior to this debt becoming due, we may engage in one or more restructuring transactions which could involve, among other things, an effective increase in interest rates, alteration of terms or exchanges involving the issuance of additional shares of common stock or other arrangements which may dilute or be adverse to the value of our common stock.

We expect to need to raise additional funds in the near future, and they may not be available on acceptable terms, or at all.

We expect that our existing cash and cash equivalents, securities available for sale and interest receivable will not be sufficient to fund our operations for the next 12 months. Accordingly, we will need to raise additional funds. We are exploring alternatives to raise additional capital through public or private equity financings, partnerships, debt financings, bank borrowings or other sources. In particular, we will need to raise additional funds to complete the PIONEER trial.

If our plans or assumptions change or are inaccurate, it will affect the amount of additional funds we will need to raise. We may raise such capital through public or private equity financings, partnerships, debt financings or restructurings, bank borrowings or other sources. Additional funding may not be available on favorable terms or at all. If adequate funds are not otherwise available, we will further curtail operations significantly, including the delay, modification or cancellation of operations and plans related to XYOTAX, pixantrone and other products we may be developing. To obtain additional funding, we may need to enter into arrangements that require us to relinquish rights to certain technologies, drug candidates, products and/or potential markets. To the extent that additional capital is raised through the sale of equity, or securities convertible into equity, shareholders may experience dilution of their proportionate ownership of us.

Table of Contents

We may be unable to obtain a quorum for our meeting of shareholders and therefore unable to take certain corporate actions.

Our bylaws require that a quorum, consisting of a majority of the outstanding shares of voting stock, be represented in person or by proxy in order to transact business at a meeting of our shareholders. A quorum was not present at our annual meeting of shareholders held on June 23, 2006. The annual meeting was therefore adjourned to allow our shareholders more time to return their proxies. If we are unable to obtain a quorum, we may be unable to take corporate actions which require the prior approval of our shareholders, including but not limited to actions such as increasing the authorized number of shares of our common stock, increasing the number of incentive options available for issuance, mergers and other matters. The failure to obtain the prior approval of our shareholders for any of these corporate actions could have a material adverse effect on the Company.

We may not receive the regulatory approvals required for us to raise funds using the Step-Up Equity Financing Agreement.

In June 2006 we announced that we had entered into a Step-Up Equity Financing Agreement with Société Générale, pursuant to which we had the option, subject to the satisfaction of certain conditions, to issue shares of our common stock to Société Générale. Société Générale would then resell such shares on the Italian stock market. One of the conditions that must be satisfied before we may issue shares pursuant to this agreement is that Société Générale and ourselves shall have received certain approvals from Italian regulatory authorities, or otherwise deemed such approvals not required. We have not received such approvals or made such a determination, and there is no guarantee that we will receive such approval or make such a determination. We will not be able to raise funds by issuing shares to Société Générale pursuant to this agreement if we are unable to receive such approval or make such a determination, and we may be unable to raise necessary funds from other sources.

We may be delayed, limited or precluded from obtaining regulatory approval of XYOTAX given that our three STELLAR phase III clinical trials for the treatment of non-small cell lung cancer did not meet their primary endpoints.

In March 2005, we announced the results of STELLAR 3, and in May 2005, we announced the results of STELLAR 2 and 4, our phase III clinical trials of XYOTAX in non-small cell lung cancer. All three trials did not achieve their primary endpoints of superior overall survival compared to current marketed agents for treating NSCLC. Preclinical and clinical data can be interpreted in different ways, which could delay, limit or preclude regulatory approval. Negative or inconclusive results or adverse medical events during a clinical trial could delay, limit or prevent regulatory approval. Our success depends in large part on obtaining regulatory approval of XYOTAX.

Without a successful PIONEER trial or positive interim results from the PIONEER trial, we expect a difficult regulatory review from the FDA for a number of reasons: our trials failed to meet their primary endpoints and the FDA has taken the view that it will not favorably review secondary endpoints on data absent achievement of primary endpoints; while gender-specific survival was pre-specified in the analysis plan, women over men gender-specific survival was not a pre-specified endpoint; and, while the FDA has recently reviewed NDAs based on pooled analyses, none have been approved in the past. We are not pursuing approval from the FDA based on non-inferiority which is usually the basis for making a comparable survival claim.

Based on discussions with the EMEA Scientific Advice Working Party, we plan to submit an MAA in Europe based on results of the STELLAR trials, specifically the STELLAR 4 trial, however a successful regulatory outcome from the EMEA is not assured as the EMEA's final opinion can not be predicted until they have had the opportunity to complete a thorough review of the clinical data that will be presented in the MAA.

We are subject to extensive government regulation.

We are subject to rigorous and extensive regulation by the FDA in the United States and by comparable agencies in other states and countries. Failure to comply with regulatory requirements could result in various

Table of Contents

adverse consequences, including possible delay in approval or refusal to approve a product, withdrawal of approved products from the market, product seizures, injunctions, monetary penalties, or criminal prosecution.

Our products may not be marketed in the United States until they have been approved by the FDA and may not be marketed in other countries until they have received approval from the appropriate agency. None of our current products have received approval. Obtaining regulatory approval requires substantial time, effort and financial resources, and we may not be able to obtain approval of any of our products on a timely basis, or at all. If our products are not approved in a timely fashion, our business and financial condition may be adversely affected.

In addition, both before and after approval, our contract manufacturers and our products are subject to numerous FDA requirements covering, among other things, testing, manufacturing, quality control, labeling, advertising, promotion, distribution and export. Manufacturing processes must conform to current Good Manufacturing Practice, or cGMPs. The FDA and other regulatory authorities periodically inspect manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money and effort to maintain compliance.

We believe that while we owned TRISENOX, which was divested to Cephalon, Inc., in July 2005, it was prescribed by physicians largely for uses not approved by the FDA. Although physicians may lawfully prescribe pharmaceutical products, such as TRISENOX, for such off-label uses, promotion by us of such off-label uses is unlawful. Some of our practices intended to make physicians aware of off-label uses of TRISENOX, without engaging in off-label promotion, could nevertheless have been construed as off-label promotion, and it is likely that some instances of off-label promotion occurred in the past. Although we have policies and procedures in place designed to assure ongoing compliance with FDA requirements regarding off-label promotion, some non-compliant actions may nevertheless have occurred. The United States Attorney's Office, or USAO, for the Western District of Washington is conducting an investigation into certain of CTI's business practices relating to TRISENOX. USAO's investigation relates to CTI's promotional practices relating to TRISENOX; its reporting of revenue relating to TRISENOX sales; and statements made by CTI representatives, and its expert third party reimbursement consultant, relating to the eligibility of TRISENOX for Medicare reimbursement when the drug was used to treat certain off-label indications. USAO has issued subpoenas to third parties relating to its investigation. CTI is fully cooperating with USAO (through the provision of documents and periodic meetings) and has not received a subpoena relating to the matter. Management cannot predict whether USAO will bring formal criminal enforcement proceedings (and USAO has not indicated that it will). Claims associated with the above-referenced as well as related conduct have been filed against the Company under seal on behalf of the government by a private party in a qui tam action. Based on information currently available to the Company, we believe that the USAO may recommend to the Department of Justice that the government intervene in the qui tam action, as is its right, and assume the conduct of this lawsuit. We believe that regardless of whether the government or the private party pursues this lawsuit that one of the primary claims that might be pursued would be that CTI violated the Federal False Claims Act by receiving reimbursement from Medicare for improper off-label use of Trisenox or otherwise ineligible sales of TRISENOX over the period ranging from October 2000 until TRISENOX's disposition to Cephalon in July of 2005. During this period the Company utilized a third party reimbursement expert. The Company believes it has meritorious defenses to these claims. It is unclear to the Company under this theory what sales or portions thereof would be in question. Accordingly, CTI cannot provide an estimate of a possible loss or range of loss in connection with this investigation or lawsuit. Under the False Claims Act, damages can be trebled and separate fines imposed for each violation, if the government or the private party plaintiff were to prevail in this lawsuit it is likely that such an adverse judgment would have a material adverse effect on our financial position, liquidity and results of operations.

Additionally, we are subject to numerous regulations and statutes regulating the manner of selling and obtaining reimbursement for our products that receive marketing approval. For example, federal statutes generally prohibit providing certain discounts and payments to physicians to encourage them to prescribe our product. Violations of such regulations or statutes may result in treble damages, criminal or civil penalties, fines or exclusion of CTI or our employees from participation in federal and state healthcare programs. Although we have policies prohibiting violations of relevant regulations and statutes, unauthorized actions of our employees or consultants (including unlawful off-label promotion), or unfavorable interpretations of such regulations or statutes may result in third-parties or regulatory agencies bringing legal proceedings or enforcement actions against us.

Table of Contents

We face direct and intense competition from our competitors in the biotechnology and pharmaceutical industries, and we may not compete successfully against them.

Competition in the oncology industry is intense and is accentuated by the rapid pace of technological development. We anticipate that we will face increased competition in the future as new companies enter the market. Our competitors in the United States and elsewhere are numerous and include, among others, major multinational pharmaceutical companies, specialized biotechnology companies and universities and other research institutions. Specifically:

If we are successful in bringing XYOTAX to market, we will face direct competition from oncology-focused multinational corporations. XYOTAX will compete with other taxanes. Many oncology-focused multinational corporations currently market or are developing taxanes, epothilones, and other cytotoxic agents, which inhibit cancer cells by a mechanism similar to taxanes, or similar products including, among others, Bristol-Myers Squibb Co., which markets paclitaxel; Aventis, which markets docetaxel; Genentech and OSI Pharmaceuticals, which market Tarceva; Genentech, which markets Avastin; Lilly, which markets Alimta; and American Pharmaceutical Partners, which markets Abraxane. In addition, several companies such as NeoPharm Inc. and Sonus Pharmaceuticals, are also developing taxane re-formulations which could compete with our products.

Because pixantrone is intended to provide less toxic treatment to patients who have failed standard chemotherapy treatment, if pixantrone is brought to market, it is not expected to compete directly with many existing chemotherapies. However, pixantrone will face competition from currently marketed anthracyclines, such as mitoxantrone (Novantrone®), and new anti-cancer drugs with reduced toxicity that may be developed and marketed.

Many of our competitors, either alone or together with their collaborators and in particular, the multinational pharmaceutical companies, have substantially greater financial resources and development and marketing teams than us. In addition, many of our competitors, either alone or together with their collaborators, have significantly greater experience than we do in developing, manufacturing and marketing products. As a result, these companies' products might come to market sooner or might prove to be more effective, less expensive, have fewer side effects or be easier to administer than ours. In any such case, sales of our products or eventual products would likely suffer and we might never recoup the significant investments we are making to develop these product candidates.

Uncertainty regarding third-party reimbursement and healthcare cost containment initiatives may limit our returns.

The ongoing efforts of governmental and third-party payors to contain or reduce the cost of healthcare may affect our ability to commercialize our products successfully. Governmental and other third-party payors continue to attempt to contain healthcare costs by:

challenging the prices charged for health care products and services,

limiting both coverage and the amount of reimbursement for new therapeutic products,

denying or limiting coverage for products that are approved by the FDA but are considered experimental or investigational by third-party payors,

refusing in some cases to provide coverage when an approved product is used for disease indications in a way that has not received FDA marketing approval, and

denying coverage altogether.

The trend toward managed healthcare in the United States, the growth of organizations such as health maintenance organizations, and legislative proposals to reform healthcare and government insurance programs could significantly influence the purchase of healthcare services and

products, resulting in lower prices and reducing

Table of Contents

demand for our products. In addition, in almost all European markets, pricing and choice of prescription pharmaceuticals are subject to governmental control. Therefore, the price of our products and their reimbursement in Europe will be determined by national regulatory authorities.

Even if we succeed in bringing any of our proposed products to the market, they may not be considered cost-effective and third-party reimbursement might not be available or sufficient. If adequate third-party coverage is not available, we may not be able to maintain price levels sufficient to realize an appropriate return on our investment in research and product development. In addition, legislation and regulations affecting the pricing of pharmaceuticals may change in ways adverse to us before or after any of our proposed products are approved for marketing.

Even if our drug candidates are successful in clinical trials, we may not be able to successfully commercialize them.

Since our inception in 1991, we have dedicated substantially all of our resources to the research and development of our technologies and related compounds. All of our compounds currently are in research or development, and none have been submitted for marketing approval.

Prior to commercialization, each product candidate requires significant research, development and preclinical testing and extensive clinical investigation before submission of any regulatory application for marketing approval. The development of anti-cancer drugs, including those we are currently developing, is unpredictable and subject to numerous risks. Potential products that appear to be promising at early stages of development may not reach the market for a number of reasons including that they may:

be found ineffective or cause harmful side effects during preclinical testing or clinical trials,

fail to receive necessary regulatory approvals,

be difficult to manufacture on a scale necessary for commercialization,

be uneconomical to produce,

fail to achieve market acceptance, or

be precluded from commercialization by proprietary rights of third parties.

The occurrence of any of these events could adversely affect the commercialization of our products. Products, if introduced, may not be successfully marketed and/or may not achieve customer acceptance. If we fail to commercialize products or if our future products do not achieve significant market acceptance, we will not likely generate significant revenues or become profitable.

If any of our license agreements for intellectual property underlying XYOTAX, pixantrone or any other products are terminated, we may lose our rights to develop or market that product.

We have licensed intellectual property, including patent applications from The University of Vermont, Hoffman La Roche and others, including the intellectual property relating to pixantrone. We have also in-licensed the intellectual property relating to our drug delivery technology that uses polymers that are linked to drugs, known as polymer-drug conjugates, including XYOTAX and CT-2106. Some of our product development programs depend on our ability to maintain rights under these licenses. Each licensor has the power to terminate its agreement with us if we fail to meet our obligations under these licenses. We may not be able to meet our obligations under these licenses. If we default under any license agreements, we may lose our right to market and sell any products based on the licensed technology.

Table of Contents

If we fail to adequately protect our intellectual property, our competitive position could be harmed.

Development and protection of our intellectual property are critical to our business. If we do not adequately protect our intellectual property, competitors may be able to practice our technologies. Our success depends in part on our ability to:

obtain patent protection for our products or processes both in the United States and other countries,

protect trade secrets, and

prevent others from infringing on our proprietary rights.

When polymers are linked, or conjugated, to drugs, the results are referred to as polymer-drug conjugates. We are developing drug delivery technology that links chemotherapy to biodegradable polymers. For example, XYOTAX is paclitaxel, the active ingredient in Taxol®, one of the world's best selling cancer drugs, linked to polyglutamate. We may not receive a patent for all of our polymer-drug conjugates and we may be challenged by the holder of a patent covering the underlying drug and/or methods for its use or manufacture.

The patent position of biopharmaceutical firms generally is highly uncertain and involves complex legal and factual questions. The U.S. Patent and Trademark Office has not established a consistent policy regarding the breadth of claims that it will allow in biotechnology patents. If it allows broad claims, the number and cost of patent interference proceedings in the United States and the risk of infringement litigation may increase. If it allows narrow claims, the risk of infringement may decrease, but the value of our rights under our patents, licenses and patent applications may also decrease. Patent applications in which we have rights may never issue as patents and the claims of any issued patents may not afford meaningful protection for our technologies or products. In addition, patents issued to us or our licensors may be challenged and subsequently narrowed, invalidated or circumvented. Litigation, interference proceedings or other governmental proceedings that we may become involved in with respect to our proprietary technologies or the proprietary technology of others could result in substantial cost to us. Patent litigation is widespread in the biotechnology industry, and any patent litigation could harm our business. Costly litigation might be necessary to protect a patent position or to determine the scope and validity of third-party proprietary rights, and we may not have the required resources to pursue any such litigation or to protect our patent rights. Any adverse outcome in litigation with respect to the infringement or validity of any patents owned by third-parties could subject us to significant liabilities to third-parties, require disputed rights to be licensed from third-parties or require us to cease using a product or technology.

We also rely upon trade secrets, proprietary know-how and continuing technological innovation to remain competitive. Third-parties may independently develop such know-how or otherwise obtain access to our technology. While we require our employees, consultants and corporate partners with access to proprietary information to enter into confidentiality agreements, these agreements may not be honored.

Our products could infringe on the intellectual property rights of others, which may cause us to engage in costly litigation and, if unsuccessful, could cause us to pay substantial damages and prohibit us from selling our products.

We attempt to monitor patent filings but have not conducted an exhaustive search for patents that may be relevant to our products and product candidates in an effort to guide the design and development of our products to avoid infringement. We may not be able to successfully challenge the validity of these patents and could have to pay substantial damages, possibly including treble damages, for past infringement and attorney's fees if it is ultimately determined that our products infringe a third-party's patents. Further, we may be prohibited from selling our products before we obtain a license, which, if available at all, may require us to pay substantial royalties. Moreover, third-parties may challenge the patents that have been issued or licensed to us. Even if infringement claims against us are without merit, or if we challenge the validity of issued patents, lawsuits take significant time, may be expensive and may divert management attention from other business concerns.

Table of Contents

We may be unable to obtain the raw materials necessary to produce our XYOTAX product candidate in sufficient quantity to meet demand when and if such product is approved.

We may not be able to continue to purchase the materials necessary to produce XYOTAX, including paclitaxel, in adequate volume and quality. Paclitaxel is derived from certain varieties of yew trees. Supply of paclitaxel is controlled by a limited number of companies. Paclitaxel is available and we purchase it from several sources. We purchase the raw material polyglutamic acid from a single source on a purchase order basis. Should the polyglutamic acid purchased from our sources prove to be insufficient in quantity or quality, should a supplier fail to deliver in a timely fashion or at all, or should these relationships terminate, we may not be able to obtain a sufficient supply from alternate sources on acceptable terms, or at all.

Our dependence on third-party manufacturers means that we do not always have sufficient control over the manufacture of our products.

We do not currently have internal analytical laboratory or manufacturing facilities to allow the testing or production of drug products in compliance with cGMPs. Because we do not directly control our suppliers, these vendors may not be able to provide us with finished product when we need it.

We will be dependent upon these third-parties to supply us in a timely manner with products manufactured in compliance with cGMPs or similar manufacturing standards imposed by foreign regulatory authorities where our products will be tested and/or marketed. While the FDA and other regulatory authorities maintain oversight for cGMP compliance of drug manufacturers, contract manufacturers may at times violate cGMPs. The FDA and other regulatory authorities may take action against a contract manufacturer who violates cGMPs. One of our products under development, XYOTAX, has a complex manufacturing process, which may prevent us from obtaining a sufficient supply of drug product for the clinical trials and commercial activities currently planned or underway on a timely basis, if at all. The active pharmaceutical ingredient and finished product for pixantrone are both manufactured by a single vendor. If the CT-2106 trials are successful and we need to manufacture additional materials for new clinical trials, we will need to identify and qualify vendors to manufacture and we may not be able to do so in a timely manner, if at all.

If we do not successfully develop additional products, we may be unable to generate significant revenue or become profitable.

We divested our sole commercial product, TRISENOX, in July 2005. XYOTAX, pixantrone and CT-2106 are currently in clinical trials and may not be successful. For example, our STELLAR phase III clinical trials for XYOTAX for the treatment of non-small cell lung cancer failed to meet their primary endpoints. A number of companies in the pharmaceutical industry, including us, have suffered significant setbacks in advanced clinical trials, even after reporting promising results in earlier trials. We will need to commit significant time and resources to develop this and additional product candidates. Our product candidates will be successful only if:

our product candidates are developed to a stage that will enable us to commercialize them or sell related marketing rights to pharmaceutical companies;

we are able to commercialize product candidates in clinical development or sell the marketing rights to third parties; and

our product candidates, if developed, are approved by the regulatory authorities.

We are dependent on the successful completion of these goals in order to generate revenues. The failure to generate such revenues may preclude us from continuing our research and development of these and other product candidates.

Table of Contents

If we are unable to enter into new licensing arrangements, our future product portfolio and potential profitability could be harmed.

One component of our business strategy is in-licensing drug compounds developed by other pharmaceutical and biotechnology companies or academic research laboratories. Substantially all of our product candidates in clinical development are in-licensed from a third-party, including XYOTAX, pixantrone and CT-2106.

Competition for new promising compounds and commercial products can be intense. If we are not able to identify future in-licensing opportunities and enter into future licensing arrangements on acceptable terms, our future product portfolio and potential profitability could be harmed.

We may take longer to complete our clinical trials than we expect, or we may not be able to complete them at all.

Before regulatory approval for any potential product can be obtained, we must undertake extensive clinical testing on humans to demonstrate the safety and efficacy of the product. Although for planning purposes we forecast the commencement and completion of clinical trials, the actual timing of these events can vary dramatically due to a number of factors.

We may not obtain authorization to permit product candidates that are already in the preclinical development phase to enter the human clinical testing phase. Authorized preclinical or clinical testing may not be completed successfully within any specified time period by us, or without significant additional resources or expertise to those originally expected to be necessary. Many drugs in human clinical trials fail to demonstrate the desired safety and efficacy characteristics. Clinical testing may not show potential products to be safe and efficacious and potential products may not be approved for a specific indication. Further, the results from preclinical studies and early clinical trials may not be indicative of the results that will be obtained in later-stage clinical trials. Data obtained from clinical trials are susceptible to varying interpretations. Government regulators and our collaborators may not agree with our interpretation of our clinical trial results. In addition, we or regulatory authorities may suspend clinical trials at any time on the basis that the participants are being exposed to unacceptable health risks or for other reasons. Completion of clinical trials depends on, among other things, the number of patients available for enrollment in a particular trial, which is a function of many factors, including the number of patients with the relevant conditions, the nature of the clinical testing, the proximity of patients to clinical testing centers, the eligibility criteria for tests as well as competition with other clinical testing programs involving the same patient profile but different treatments.

We have limited experience in conducting clinical trials. We expect to continue to rely on third-parties, such as contract research organizations, academic institutions and/or cooperative groups, to conduct, oversee and monitor clinical trials as well as to process the clinical results and manage test requests, which may result in delays or failure to complete trials, if the third-parties fail to perform or to meet the applicable standards.

If we fail to commence or complete, need to perform more or larger clinical trials than planned or experience delays in any of our present or planned clinical trials, our development costs may increase and/or our ability to commercialize our product candidates may be adversely affected. If delays or costs are significant, our financial results and our ability to commercialize our product candidates may be adversely affected.

If we fail to establish and maintain collaborations or if our partners do not perform, we may be unable to develop and commercialize our product candidates.

We have entered into collaborative arrangements with third-parties to develop and/or commercialize product candidates and are currently seeking additional collaborations. For example, we entered into an agreement with the Gynecologic Oncology Group to perform a phase III trial of XYOTAX in patients with ovarian cancer. Additional collaborations might be necessary in order for us to fund our research and development activities and third-party manufacturing arrangements, seek and obtain regulatory approvals and successfully commercialize our existing and future product candidates. If we fail to enter into additional collaborative arrangements or fail to maintain our existing collaborative arrangements, the number of product candidates from which we could receive future revenues would decline.

Table of Contents

Our dependence on collaborative arrangements with third-parties will subject us to a number of risks that could harm our ability to develop and commercialize products, including that:

collaborative arrangements may not be on terms favorable to us;

disagreements with partners may result in delays in the development and marketing of products, termination of our collaboration agreements or time consuming and expensive legal action;

we cannot control the amount and timing of resources partners devote to product candidates or their prioritization of product candidates and partners may not allocate sufficient funds or resources to the development, promotion or marketing of our products, or may not perform their obligations as expected;

partners may choose to develop, independently or with other companies, alternative products or treatments, including products or treatments which compete with ours;

agreements with partners may expire or be terminated without renewal, or partners may breach collaboration agreements with us;

business combinations or significant changes in a partner's business strategy might adversely affect that partner's willingness or ability to complete its obligations to us; and

the terms and conditions of the relevant agreements may no longer be suitable.

The occurrence of any of these events could adversely affect the development or commercialization of our products.

Because we base several of our drug candidates on unproven novel technologies, we may never develop them into commercial products.

We base several of our product candidates upon novel technologies that we are using to develop drugs for the treatment of cancer. These technologies have not been proven. Furthermore, preclinical results in animal studies may not predict outcomes in human clinical trials. Our product candidates may not be proven safe or effective. If these technologies do not work, our drug candidates may not develop into commercial products.

We are required to comply with the regulatory structure of Italy because our stock is traded on the Nuovo Mercato, which could result in administrative challenges.

Our stock is traded on the MTAX market and we are required to also comply with the rules and regulations of CONSOB and Borsa Italiana, which collectively regulate companies listed on Italy's public markets. Conducting our operations in a manner that complies with all applicable laws and rules requires us to devote additional time and resources to regulatory compliance matters. For example, the process of seeking to understand and comply with the laws of each country, including tax, labor and regulatory laws, might require us to incur the expense of engaging additional outside counsel, accountants and other professional advisors and might result in delayed business initiatives as we seek to ensure that each new initiative will comply with all regulatory regimes.

We are subject to additional legal duties, additional operational challenges and additional political and economic risks related to our operations in Italy.

A portion of our business is based in Italy. We are subject to duties and risks arising from doing business in Italy, such as:

Italian employment law, including collective bargaining agreements negotiated at the national level and over which we have no control;

European data protection regulations, under which we will be unable to send private personal data, including many employment records and some clinical trial data, from our Italian offices to our U.S. offices

Table of Contents

until our U.S. offices self-certify their adherence to the safe harbor framework established by the U. S. Department of Commerce in consultation with the European Commission;

tariffs, customs, duties and other trade barriers; and

capital controls, terrorism and other political risks.

We are also subject to the following operational challenges, among others, as a result of our merger with Novuspharma and having a portion of our business and operations based in Italy:

effectively pursuing the clinical development and regulatory approvals of all product candidates;

successfully commercializing products under development;

coordinating research and development activities to enhance introduction of new products and technologies;

coalescing the Italian business culture with our own and maintaining employee morale; and

maintaining appropriate uniform standards, controls, procedures and policies relating to financial reporting and employment related matters, and the conduct of development activities that comply with both U.S. and Italian laws and regulations.

We may not succeed in addressing these challenges, risks and duties, any of which may be exacerbated by the geographic separation of our operations in the United States and in Italy. These risks related to doing business in Italy could harm the results of our operations.

Because there is a risk of product liability associated with our products, we face potential difficulties in obtaining insurance.

Our business exposes us to potential product liability risks inherent in the testing, manufacturing and marketing of human pharmaceutical products, and we may not be able to avoid significant product liability exposure. While we have insurance covering product use in our clinical trials, it is possible that we will not be able to maintain such insurance on acceptable terms or that any insurance obtained will provide adequate coverage against potential liabilities. Our inability to obtain sufficient insurance coverage at an acceptable cost or otherwise to protect against potential product liability claims could prevent or limit the commercialization of any products we develop. A successful product liability claim in excess of our insurance coverage could exceed our net worth.

Since we use hazardous materials in our business, we may be subject to claims relating to improper handling, storage or disposal of these materials.

Our research and development activities involve the controlled use of hazardous materials, chemicals and various radioactive compounds. We are subject to international, federal, state, and local laws and regulations governing the use, manufacture, storage, handling and disposal of such materials and certain waste products. Although we believe that our safety procedures for handling and disposing of such materials comply with the standards prescribed by state and federal regulations, the risk of accidental contamination or injury from these materials cannot be eliminated completely. In the event of such an accident, we could be held liable for any damages that result and any such liability not covered by insurance could exceed our resources. Compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development or production efforts.

Table of Contents

We may not be able to conduct animal testing in the future, which could harm our research and development activities.

Certain of our research and development activities involve animal testing. Such activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting activities through protests and other means. To the extent the activities of these groups are successful, our business could be materially harmed by delaying or interrupting our research and development activities.

Our operations in Italy make us subject to increased risk regarding currency exchange rate fluctuations.

As a result of operations in Italy, we are exposed to risks associated with foreign currency transactions insofar as we use U.S. dollars to make contract payments denominated in euros or vice versa. As the net positions of our foreign currency transactions might fluctuate, our earnings might be negatively affected. In addition, we are exposed to risks associated with the translation of euro-denominated financial results and accounts into U.S. dollars. Our reporting currency will remain as the U.S. dollar; however, a portion of our consolidated financial obligations will arise in euros. In addition, the carrying value of some of our assets and liabilities will be affected by fluctuations in the value of the U.S. dollar as compared to the euro. Changes in the value of the U.S. dollar as compared to the euro might have an adverse effect on our reported results of operations and financial condition.

Risks Related To The Securities Markets

Our stock price is extremely volatile, which may affect our ability to raise capital in the future and may subject the value of your investment in our securities to sudden decreases.

The market price for securities of biopharmaceutical and biotechnology companies, including ours, historically has been highly volatile, and the market from time to time has experienced significant price and volume fluctuations that are unrelated to the operating performance of such companies. For example, during the twelve month period ended June 30, 2006, our stock price ranged from a low of \$1.31 to a high of \$3.49. Fluctuations in the trading price or liquidity of our common stock may adversely affect the value of your investment in our common stock.

Factors that may have a significant impact on the market price and marketability of our securities include:

announcements by us or others of results of preclinical testing and clinical trials and regulatory actions;

announcements of technological innovations or new commercial therapeutic products by us, our collaborative partners or our present or potential competitors;

the issuance of additional debt, equity or other securities;

our quarterly operating results;

developments or disputes concerning patent or other proprietary rights;

developments in our relationships with collaborative partners;

acquisitions or divestitures;

litigation and government proceedings;

adverse legislation, including changes in governmental regulation;

third-party reimbursement policies;

changes in securities analysts' recommendations;

changes in health care policies and practices;

Table of Contents

economic and other external factors; and

general market conditions.

In the past, following periods of volatility in the market price of a company's securities, securities class action litigation has often been instituted. In the case of our company, beginning in March 2005, several class action lawsuits were instituted against CTI, James Bianco and Max Link and a derivative action lawsuit was filed against CTI's full board of directors. See the section under the heading "Legal Proceedings." As a result of these lawsuits, we could incur substantial legal fees and our management's attention and resources could be diverted from operating our business as we respond to the litigation.

Anti-takeover provisions in our charter documents, our shareholder rights plan, and under Washington law could make removal of incumbent management or an acquisition of us, which may be beneficial to our shareholders, more difficult.

Provisions of our articles of incorporation and bylaws may have the effect of deterring or delaying attempts by our shareholders to remove or replace management, to commence proxy contests, or to effect changes in control. These provisions include:

a classified board so that only approximately one third of the board of directors is elected each year;

elimination of cumulative voting in the election of directors;

procedures for advance notification of shareholder nominations and proposals;

the ability of our board of directors to amend our bylaws without shareholder approval;

the ability of our board of directors to issue up to 10,000,000 shares of preferred stock without shareholder approval upon the terms and conditions and with the rights, privileges and preferences as the board of directors may determine; and

a shareholder rights plan.

In addition, as a Washington corporation, we are subject to Washington law which imposes restrictions on some transactions between a corporation and certain significant shareholders.

These provisions, alone or together, could have the effect of deterring or delaying changes in incumbent management, proxy contests or changes in control.

Item 4. Submission of Matters to a Vote of Security Holders

We convened our annual meeting of shareholders on June 23, 2006. At the annual meeting, our shareholders were asked to take action on the following proposals:

- (1) elect two Class III directors to serve until the 2009 Annual Meeting and to elect one Class I director to serve until the 2007 Annual Meeting;

Edgar Filing: CELL THERAPEUTICS INC - Form 10-Q/A

- (2) approve an amendment to our amended and restated articles of incorporation to increase the number of authorized shares of common stock from 200,000,000 to 350,000,000, including amending and restating our articles of incorporation;

- (3) approve an amendment to our 1996 Employee Stock Purchase Plan to extend the term of such plan from 10 years from the date of the approval of such plan by our shareholders, or April 29, 2006, to 20 years from the date of approval of such plan by our shareholders, or April 29, 2016;

Table of Contents

- (4) approve an amendment to our 2003 Equity Incentive Plan previously approved by the board of directors to (a) increase the number of shares subject to the initial automatic grant of nonqualified stock options to non-employee directors upon joining the board of directors from 15,000 shares to 24,000 shares (the Initial Grant), (b) change the vesting of the Initial Grant from being fully vested at the date of grant to becoming vested after one year, (c) change, in part, the expiration of all option grants to non-employee directors from (i) three months following the cessation of such director's service on the board of directors for any reason other than death or disability and (ii) one year following the cessation of such director's service on the board by reason of death or disability to three years following the cessation of such director's service on the board of directors in all such cases, (d) alter the formula whereby directors may convert cash compensation into shares of common stock from an option pricing model determined by the board of directors to a rate of \$3 in option grant value for every \$1 in cash so converted (e) increase the number of shares available for issuance under such plan by 6,000,000 shares, and (f) increase the maximum number of shares that may be issued pursuant to all awards granted to an individual in any one fiscal year under the 2003 Plan to 750,000 shares;
- (5) approve the issuance of common stock at our election in connection with the payment of interest and make-whole amounts that may become due under our 7.5% convertible senior notes due 2011; and
- (6) ratify the selection of Stonefield Josephson, Inc. as our independent auditors for the year ending December 31, 2006 (collectively, the Proposals).

Our bylaws require that a quorum, consisting of a majority of the outstanding shares of voting stock, be represented in person or by proxy in order to transact business at the annual meeting. A quorum was not present and no action was taken regarding any of the Proposals.

As permitted by Washington state law, we adjourned the annual meeting until a later date in order to give additional time for shareholders to return their proxies. We have not yet determined the date upon which the meeting will be continued. We may not be able to reach a quorum at such reconvened meeting and cannot guarantee that any of the Proposals will receive shareholder approval. Please see the discussion under Risk Factors *We may be unable to obtain a quorum for our meeting of shareholders and therefore unable to take certain corporate actions.*

Pursuant to our bylaws, each director will continue to hold office until his or her successor has been elected. Therefore, the directors of the Company will continue to be John H. Bauer, James, A. Bianco, M.D., Vartan Gregorian, Ph.D, Mary O. Munding, Dr.PH, Phillip M. Nudelman, Ph.D and Jack W. Singer, M.D.

Item 6. Exhibits

(a) Exhibits

- 15 Letter Regarding Unaudited Interim Financial Information
- 31.1 Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2 Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32 Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized:

CELL THERAPEUTICS, INC.
(Registrant)

Dated: February 5, 2007

By: /s/ James A. Bianco, M.D.
James A. Bianco, M.D.
President and Chief Executive Officer

Dated: February 5, 2007

By: /s/ Louis A. Bianco
Louis A. Bianco
Executive Vice President,
Finance and Administration
(Principal Financial Officer,
Chief Accounting Officer)